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Abstract 
 This dissertation primarily describes investigations of the mechanisms by which 
pentameric ligand-gated ion channels (pLGICs) activate (“gating”) using canonical and 
non-canonical amino acid mutagenesis. Chapter 1 provides an introduction to the systems 
being studied, their physiological roles, and the techniques that we have used to study them. 
Chapter 2 describes a series of experiments comparing the roles of amino acid residues 
proximal to the neurotransmitter binding site in the type 3 serotonin receptor (5-HT3R) to 
the aligning residues of the muscle-type nicotinic acetylcholine receptor (nAChR). The 
findings presented in Chapter 3 assess the functional roles of proline residues in the 
prokaryotic pLGIC, Erwinia ligand-gated ion channel (ELIC). Chapter 4 describes an 
extensive investigation of salient details of 5-HT3R gating using canonical and non-
canonical amino acid mutagenesis of amino acid residues at the interface of the 
extracellular domain and transmembrane domain of this receptor. Chapter 5 applies a 
photocrosslinking strategy employing the non-canonical amino acid p-azidophenylalanine 
to study dimerization and cofactor interactions of the estrogen receptor α. 
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Chapter 1: Introduction 
1.1 Neurotransmission  
1.1.1 Ion channels 
The brain is the central hub of the nervous system, housing approximately 100 
billion neurons by some estimates, each of which may have on the order of 10,000 points 
of connection with others neurons.1 At these points of connection, known as synapses, 
presynaptic cells communicate via electrochemical signals to postsynaptic cells. This 
process of neurotransmission proceeds by means of action potentials, in which a wave of 
cell membrane depolarization propagates down the length of an axon connecting two 
neurons via the action of voltage-gated ion channels (Figure 1.1A).2,3 These proteins span 
the cell membrane and allow selective passage of ions across the membrane in response to 
changes in cell potential, thus carrying the signal along. This electrochemical signal 
ultimately reaches the synapse, at which point a signal is conveyed to the postsynaptic cell 
via the release of neurotransmitters across the synaptic cleft (Figure 1.1B).4,5  
 A key role of neurotransmitters is the activation of ligand-gated ion channels 
(LGICs) on the postsynaptic cell surface (Figure 1.1C).6–8 Like voltage-gated ion 
channels, LGICs are transmembrane proteins that permit the passage of select ions across 
the cell membrane in response to an external stimulus, only LGICs respond to small 
molecule neurotransmitters rather than changes in cell potential. The activation of LGICs 
on postsynaptic cells generates postsynaptic potentials that can be excitatory (causing 
depolarization of the cell) or inhibitory (causing hyperpolarization of the cell) depending 
on the nature of the neurotransmitters released at the synapse and the expression levels of 
different LGICs on the postsynaptic cell surface. In turn, the resultant postsynaptic 
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potentials make the postsynaptic cell more or less likely to fire an action potential, 
respectively. LGICs thus play a crucial role in the process of neurotransmission.  
 Given their important role in neurotransmission, LGICs are implicated in a wide 
range of conditions.9–20 Members of the nicotinic acetylcholine receptor (nAChR) family, 
for example, are involved in nicotine addiction,21,22 while another member of the family is 
implicated in myasthenia gravis.23 Inhibitors of type 3 serotonin receptors (5-HT3Rs) are 
prescribed to treat nausea and vomiting, yet these receptors have also been implicated in a 
number of mood disorders.10 Our collective understanding of LGICs – their functions, 
regulation, pharmacologies, and mechanisms of action – is therefore critical to the 
treatment of a broad array of disorders. 
1.1.2 Pentameric ligand-gated ion channels 
 
Figure 1.1. The process of neurotransmission. (A) Signals travel between neurons by 
means of action potentials. (B) Neurotransmitters carry forth a signal at the synapses 
where neurons meet. (C) Ligand-gated ion channels respond to neurotransmitters to 
conduct ions across the postsynaptic cell membrane.  
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 A subset of LGICs, sharing a 
highly-conserved overall structure, is the 
pentameric ligand-gated ion channel 
(pLGIC) family.7,8,24,25 The pLGICs that 
are found in vertebrates are also known as 
Cys-loop receptors, due to the presence of 
a conserved disulfide-bonded loop that is 
closely involved in receptor function. 
Members of the Cys-loop receptor family 
include the excitatory nAChRs26 and 5-
HT3Rs
27 as well as the inhibitory type A γ-
aminobutyric acid receptors 
(GABAARs)
28 and glycine receptors 
(GlyRs).29 There are also two pLGICs that 
are found in prokaryotes, namely 
Gleobacter ligand-gated ion channel 
(GLIC)30 and Erwinia31 ligand-gated ion 
channel (ELIC).32,33 These pLGICs have 
proven to be much more amenable to 
crystallization than Cys-loop receptors, 
 
Figure 1.2. General structure of Cys-loop receptors and other pLGICS. (A) Overall 
topology of a single pentameric channel, illustrating the concentric arrangement around 
a central pore. (B) View of two adjacent receptor subunits, highlighting the multidomain 
architecture. (C) Neurotransmitter binding site between adjacent subunits. Binding 
loops A-E are colored red, orange, yellow, green, blue, purple, respectively. The bound 
ligand, nicotine, is shown in cyan. PDB ID 5KXI.31 
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which has made them a valuable model system for studying the structure and mechanics of 
pLGICs.7,25  
A single Cys-loop receptor consists of five subunits assembled in a concentric 
fashion about an axis that passes through the channel pore (Figure 1.2A). Each individual 
subunit is composed of three domains: 1) an extracellular domain (ECD), consisting 
primarily of ten ß-strands which together assemble into a ß-sandwich, 2) a transmembrane 
domain (TMD) contributed by four α-helices, numbered M1-M4, and 3) an intracellular 
domain (ICD) between the M3 and M4 helices that varies considerably between different 
receptors and receptor subtypes (Figure 1.2B). Note that the prokaryotic pLGICS GLIC 
and ELIC are highly structurally homologous to Cys-loop receptors, but lack the disulfide 
of the signature Cys-loop and likewise lack the intracellular M3-M4 loop.25  
 Over the last 20+ years of structural, functional, and computational studies of 
pLGICs, many of the general details of receptor activation have become relatively 
clear.7,8,24,34,35 Endogenous neurotransmitter agonists bind in the ECDs of these receptors 
at interfaces between adjacent subunits, known as the orthosteric binding sites. 
Noncovalent interactions are formed between ligands six canonical binding site “loops” of 
the receptors, designated loops A-E (Figure 1.2C). These are referred to as loops mainly 
for historical reasons, as several contain substantial ß-sheet structure. Binding of agonist 
causes a series of structural rearrangements collectively referred to as “gating,” starting 
with residues immediately in and around the binding site, perhaps most notably a 
“clamping” of the otherwise flexible loop C around the ligand. This ligand binding event 
causes a quaternary twisting of the ECD relative to the TMD as well as rearrangements of 
several loop structures at the ECD-TMD interface. These rearrangements ultimately result 
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in displacement of the pore-lining M2 helices in such a way that enables the conduction of 
ions through the pore, which is otherwise occluded by a hydrophobic constriction.   
 While the global changes underlying pLGIC activation are relatively well-
characterized, intimate molecular details are lacking in many areas. Over the years, our lab 
has contributed greatly to understanding and characterizing noncovalent interactions 
between pLGICs and the ligands they bind via structure-function studies, most notably by 
means of non-canonical amino acid mutagenesis (section 1.3).36,37 Much of the research 
presented in this dissertation, however, has sought to derive insights into the more nebulous 
process of receptor gating.  
1.2 Transcriptional Regulation by Estrogen Receptor α 
 Another means of cellular signaling is achieved by small molecule messengers that 
regulate the transcription of target genes. One large class of proteins responsible for 
carrying out this regulation is the nuclear receptor family of transcription factors.38 These 
receptors bind hormones and affect transcription via recruitment of transcriptional 
machinery to hormone response elements within the promoters of target genes. 
 One important member of the nuclear receptor family is the estrogen receptor α 
(ERα).39,40 As one can tell from its name, the function of ERα is to control the transcription 
of target genes in response to endogenous estrogens, although a structurally diverse array 
of exogenous compounds also has activity at ERα.41–43 Oncogenic activation of the 
estrogen receptor signaling pathway occurs in many different cancers, perhaps most 
notably in breast cancer.44–49 The ERα-targeting drug tamoxifen is widely prescribed in the 
treatment of breast cancer, with millions of people taking tamoxifen across the world every 
year.50 
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  As with all members of the nuclear receptor family, ERα is a soluble multidomain 
protein, with each domain contributing to receptor function.40,51–54 In order of primary 
sequence, the domains of ERα (Figure 1.3A) are the N-terminal domain (NTD), which 
contains a transcriptional “activation function” (AF-1) and is highly intrinsically 
disordered, the DNA-binding domain (DBD), which is mainly responsible for recognizing 
estrogen response elements (EREs), the hinge domain (H), which connects the DBD to the 
ligand-binding domain (LBD), and finally the LDB itself, which binds estrogen and is 
 
Figure 1.3. Signaling via ERα. (A) Domain organization of ERα. (B) General 
mechanism of action of ERα in response to E2.  
7 
 
mostly responsible for the estrogen-dependent transcriptional activity (“activation function 
2”, or AF-2).  
The general mechanism of action of ERα in response to estrogens such as ß-
estradiol (E2) is depicted in Figure 1.3B.39,43,53 In the absence of activating estrogens, ERα 
resides in the cytosol as a complex with Hsp90, among other chaperones. Upon binding of 
an activating estrogen such as E2, ERα dissociates from Hsp90, dimerizes, and translocates 
to the nucleus, where it binds EREs as well as coactivators and, ultimately, RNA 
polymerase (RNAP) to transcribe target genes. In this simple scenario, ERα responds to 
E2 to upregulate target genes, however the activity of ERα is tightly regulated.55–60 There 
are numerous sites of post-translational modification within ERα that affect function, and 
the relative abundances of coactivator and corepressor proteins can completely change the 
response of ERα to different estrogens in different cellular environments. In this 
dissertation, we have built upon previous work in the Dougherty lab to develop tools to 
study dimerization and sites of interaction between cofactors and the NTD of ERα.  
1.3 Non-canonical Amino Acid Mutagenesis 
 Conventional site-directed mutagenesis is an invaluable technique for conducting 
biochemical investigations of proteins. There are, however, only 20 canonical naturally-
occurring amino acids that together make up most of the proteins we know. We are thus 
limited in the range of side-chain functionalities we can easily and site-specifically 
introduce into proteins using endogenous translational machinery.  
 When different chemistries are needed, there are two methods of hijacking protein 
translation to site-specifically introduce non-canonical amino acids (NCAAs) into 
proteins.61 Both of these methods rely on the use of tRNAs originally identified in 
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microorganisms that incorporate their cognate amino acids in response to sequences 
corresponding to nonsense codons in most other organisms; thus these methods are known 
generally as “nonsense suppression.”  
In one approach to nonsense suppression used extensively by our lab (Figure 1.4), 
the chemical aminoacylation method,62 a circular plasmid is first mutated at the site of 
interest to a nonsense codon (most commonly TAG) using PCR-based methods, and the 
DNA is linearized and transcribed in vitro to yield mRNA. Separately, nearly-full-length 
suppressor tRNA that recognizes the stop codon is produced by in vitro runoff 
transcription, and is subsequently enzymatically ligated to the final deoxynucleic acid two-
mer of the tRNA that has been chemically aminoacylated to a NCAA. Directly introducing 
the mRNA and the charged tRNA into cells thus gives them everything they need to 
incorporate a NCAA at the site of interest. A convenient expression system for this 
 
Figure 1.4. Nonsense suppression via the chemical aminoacylation method, using a 
Xenopus laevis oocyte expression system.  
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approach to NCAA mutagenesis is the Xenopus laevis oocyte, which is large enough 
(~1mm in diameter) that microinjection can be used to introduce the mRNA and aminoacyl 
tRNA.63 This method of NCAA mutagenesis is able to introduce an impressively broad 
range of amino acids and amino acid analogues, limited only by the permissiveness of the 
ribosome. Still, it suffers from a number of other limitations, foremost of which are the 
limited amount of protein that can be produced, the labor-intensive process of preparing 
aminoacylated tRNA in vitro, and the complications of working with RNA in vitro that 
come with its instability relative to DNA.  
Another method (Figure 1.5) of nonsense suppression circumvents many of the 
drawbacks of the above-described method, but comes with its own limitations. Originally 
 
Figure 1.5. Nonsense suppression via the “synthetase method.”  
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developed in the lab of Prof. Peter Schultz,64,65 this method requires only DNA to be 
introduced into the heterologous expression system. Two expression vectors are 
introduced: one for the protein of interest, again with a nonsense mutation (most commonly 
TAG) at the specified site for incorporation of a NCAA, and another encoding the 
suppressor tRNA alongside an engineered aminoacyl tRNA synthetase that is able to 
charge the suppressor tRNA with a free NCAA that is included in the growth medium. 
Given that this method relies on the action of a synthetase to aminoacylate the suppressor 
tRNA, we colloquially refer to this technique as the “synthetase method.” This method 
yields greater amounts of protein than the aforementioned approach, but suffers from the 
need to engineer a new orthogonal tRNA/synthetase pair for any new NCAA that one 
would like to incorporate. Thus both are useful methods, but excel at different applications.  
1.4 Structure-function Analysis of pLGICs 
1.4.1 Two-electrode voltage clamp electrophysiology 
 Electrophysiology is a very powerful method for characterizing ion channel 
function.66 While several electrophysiological methods exist, our lab has primarily used 
two-electrode voltage clamp (TEVC) electrophysiology to characterize ion channel 
function (Figure 1.6A). In this setup, cells (in our case, Xenopus laevis oocytes) are 
impaled with two electrodes: a voltage electrode for monitoring cell potential over the 
course of the experiment, and a current electrode for injecting current into cells to “clamp” 
them at a constant membrane potential. Throughout the course of the experiment, the 
amount of injected current needed to maintain the clamped membrane potential is recorded, 
and serves as a readout of ion flux across the membrane. This technique can be used to 
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record currents as small as tens of 
nanoamps, and thus can be used to 
measure responses from very small 
numbers of ion channels.  
 We use TEVC to generate dose-
response curves in the characterization of 
ion channels in structure-function 
studies.36,67 Starting with a low 
concentration of agonist and applying 
successively larger concentrations, we 
measure the current flux across the cell 
membrane up to some maximum value, 
Imax, at which point a maximal number of 
ion channels are active (Figure 1.6B). The 
value for Imax varies between experiments, 
however in the analysis of the data, each 
response is normalized to the Imax, which 
is set to one. Averaging these dose-
response relationships for individual cells 
yields a composite dose-response curve. 
We then fit these data to the Hill equation,  
𝐼𝑛𝑜𝑟𝑚 =
1
[1 + (
𝐸𝐶50
[𝑎𝑔𝑜𝑛𝑖𝑠𝑡]
)
𝑛𝐻
]
 
 
Figure 1.6. Functional characterization of 
pLGICs via TEVC. (A) TEVC setup, using 
a Xenopus laevis oocyte. (B) Raw data; 
current traces in response to agonist. (C) 
Dose-response curves illustrating wild-
type, gain of function (GOF), and loss of 
function (LOF) variants. 
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where Inorm is the normalized current at a given concentration of agonist, nH is the Hill 
coefficient (a measure of cooperativity), and EC50 is the effective concentration for a half-
maximal response (a measure of agonist sensitivity). The metric we mainly compare is 
EC50. Mutations that make receptors more sensitive to agonist, deemed “gain-of-function”, 
shift the curve to lower EC50 values, while those that shift the EC50 to higher values are 
called “loss-of-function” mutants (Figure 1.6C). We consider differences in EC50 greater 
than two-fold to be meaningfully different. Notably, changes in EC50 may reflect changes 
in both the binding of ligand and changes in receptor gating.  
1.4.2 Mutant cycle analysis 
 Beyond interpreting changes in EC50, one can perform double-mutant cycle 
analysis in order to quantify interactions between mutations.68,69 In a double-mutant cycle 
analysis (Figure 1.7A) of two residues in a pLGIC, dose-response data are collected and 
EC50 values are determined and compared between wild-type receptors, the two single-
mutant receptors, and the double-mutant receptor. These EC50 values are then used to 
define a “coupling parameter,” Ω: 
Ω =
EC50(𝑤𝑡) ∗ 𝐸𝐶50(𝐴𝐵)
EC50(𝐴) ∗ 𝐸𝐶50(𝐵)
 
where A and B denote single-mutant receptors and AB designates the double-mutant 
receptor. This coupling parameter quantifies the extent to which the effects of two 
mutations deviate from additivity. The extent of this deviation is further reflected in a G 
value, the difference in the free energy of activation between the expected (additive) value 
versus the observed value for the double mutant, given by the equation   
G = R ∗ T ∗ ln⁡(Ω) 
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where R is the gas constant and T is the temperature in kelvins. We consider deviations 
from additivity ≥ 2-fold (Ω ≥ 2 or Ω ≤ 0.5) to constitute “meaningful” functional coupling 
of the mutations. This corresponds to |G| ≥ 0.40 kcal•mol-1. The sign of G has to do 
with the directionality of the deviation from additivity (ie, whether the EC50 is higher or 
lower than expected), however we report |G| values throughout, as the magnitude of the 
coupling energy can be used as a general readout of the functional cooperativity between 
pairs of mutations, with higher values indicating stronger cooperation.  
 Mutant cycle analysis can be further used to quantify the cooperativity between 
three mutations as a unit in a so-called triple mutant cycle analysis.70 In this type of 
analysis, depicted pictorially as a cube (Figure 1.7B), EC50 values are determined for wild-
type receptors, three single-mutant and double-mutant receptors, and a triple mutant 
receptor with all three mutations. In the case when the three mutations of interest do 
function as a unit, each double-mutant cycle between two mutations on a wild-type 
background will yield a meaningful G value, while the G values of the mutant cycles 
 
Figure 1.7. Cartoon representations of (A) double-mutant cycle analysis and (B) triple-
mutant cycle analysis. G and G values are determined as described in the text. 
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on the opposite faces of the cube will drop to nearly 0 kcal•mol-1. These opposing faces of 
the cube represent the equivalent mutant cycle in the background of the third mutation, the 
presence of which should remove energetic coupling between the other two mutations if 
the three do indeed function as a co-dependent unit. We then define a coupling energy for 
the triad as a whole, a G value, calculated by taking the difference between any two 
opposite faces of the cube. The G thus describes the difference between G values 
for double mutant cycles between two mutations in the presence and absence of the third 
mutation, and greater values of G reflect a greater energetic dependence among 
residues of the triad.  
1.5 Probing Protein-Protein Interactions using Photocrosslinking Non-canonical 
Amino Acids 
 Protein-protein interactions are ubiquitous in biological systems, serving many 
different functions, including many of clinical relevance.71–73 Understanding the nature of 
particular protein-protein interactions and developing tools to better study them is thus 
invaluable to our ability to address issues of human health and disease. 
The use of non-canonical amino acids bearing photoreactive side-chain groups can 
be very useful for the mapping of protein-protein interaction interfaces and for the 
identification of novel interacting partners of a protein of interest.74,75 Using the synthetase 
method (section 1.3), one can introduce a NCAA such as 4-benzoylphenylalanine, p-
azidophenylalanine (N3Phe), or any of a number of amino acids containing a diazirine 
group site-specifically into a protein and irradiate with UV light to generate a radical 
species that can react with a nearby interactor to form a chemical crosslink. The reaction 
mechanism for crosslinking using N3Phe is shown in Figure 1.8. Crosslinked complexes 
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can be purified for downstream analysis using antibodies against the protein of interest or 
affinity tags. Photocrosslinking can then be combined with low-resolution methods like 
western blotting or higher-resolution methods like mass spectrometry to characterize 
and/or identify the crosslinked products.76,77  
 There are several advantages to using photocrosslinking NCAAs over other 
methods of isolating interacting proteins.74,78 First off, methods such as co-
immunoprecipitation that rely on noncovalent interactions between the protein of interest 
and interacting partners may miss weaker interactions that may nonetheless be functionally 
relevant. This can be circumvented by using chemical crosslinking methods to create 
covalent complexes between the target and the protein of interest. However, this approach 
suffers from the lack of generality of the crosslinking reaction: chemical crosslinkers 
depend on the presence of certain functional groups, most notably the primary amines of 
lysine side-chains and the thiols of cysteine side-chains, that may not be present in the 
protein-protein interface, which itself may not be accessible to the crosslinker. On the other 
hand, the radical species generated via irradiation of photoreactive NCAAs insert into a 
 
Figure 1.8. Site-specific crosslinking using the NCAA, N3Phe. Expulsion of N2 
generates a reactive nitrene that can react directly with X-H bonds or rearrange to the 
ketenimine, whereupon crosslinking can occur via nucleophilic attack. 
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broad range of bonds, including relatively inert C-H bonds that cannot otherwise be 
chemically crosslinked. Finally, photocrosslinking NCAAs can be used to detect protein-
protein interactions in live cells with high spatiotemporal control while introducing 
minimal perturbations to the protein of interest. This exquisite combination of control and 
specificity cannot be found with any other method.  
1.6 Summary of Dissertation Work 
 In this dissertation, canonical and non-canonical amino acid mutagenesis have been 
used alongside other techniques to perform structure-function studies of pLGICs and probe 
protein-protein interactions of ERα. The results described herein constitute basic science 
investigations of protein function, and contribute to our collective knowledge of pLGICs 
and nuclear receptors, which we hope will have lasting impact on the field. 
 Chapter 2 describes an investigation of amino acid residues involved in the early 
steps of gating in the 5-HT3AR and the muscle-type nAChR. Using canonical site-directed 
mutagenesis to perform an extensive series of double mutant cycle analyses and a triple 
mutant cycle analysis, we compare the contributions of a triad of residues immediately 
adjacent to the orthosteric agonist binding site in these two receptors. We further analyze 
how this triad of residues affects ligand selectivity in the 5-HT3AR, and extend the study to 
other residues previously implicated in receptor gating. 
 Chapter 3 presents an investigation of the roles of proline residues in the 
prokaryotic pLGIC, ELIC. Proline is unique among the naturally-occurring amino acids, 
being the only amino acid with a side chain that is cyclized onto the peptide backbone, 
which imbues proline with properties unseen in the other amino acids. By conducting an 
initial alanine scan of the proline residues in ELIC, we identify those that are most critical 
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for receptor function. An extensive investigation of the one proline found to be critical for 
ELIC function via non-canonical amino acid mutagenesis provides insights into the salient 
chemical features of this residue.  
 Chapter 4 combines canonical and non-canonical amino acid mutagenesis in a 
structure-function study of the region at the interface of the ECD and TMD of the 5-HT3AR. 
This region has been previously implicated in receptor gating of various pLGICs. We add 
upon what was previously known about the workings of this key gating region by 
characterizing function of various 5-HT3AR single-mutants, and further combining these 
mutations in double-mutant cycle analyses to quantify energetic cooperativity between 
residues in the ECD-TMD interface.  
 Chapter 5 builds off of previous work in our group to use site-specific incorporation 
of a photocrosslinking NCAA in ERα overexpressed in mammalian cells in order to 
quantify receptor homodimerization in response to different drugs, as well as to identify 
novel interactions between cofactors and the ERα NTD. Using this method, we 
successfully demonstrate dose-dependent ERα dimerization in response to ß-estradiol (E2), 
4-hydroxytamoxifen (4-OHT), the active metabolite of the anticancer drug tamoxifen, and 
ICI-182780 (fulvestrant), another anticancer drug. We also use photocrosslinking and 
visualization by western blotting to identify several potential sites within the ERα NTD for 
cofactor interactions.  
1.7 References 
1. von Bartheld, C. S., Bahney, J. & Herculano-Houzel, S. The Search for True 
Numbers of Neurons and Glial Cells in the Human Brain: A Review of 150 Years of 
Cell Counting. J. Comp. Neurol. 524, 3865–3895 (2016). 
2. Lodish, H. et al. The Action Potential and Conduction of Electric Impulses. Mol. Cell 
Biol. 4th Ed. (2000). 
18 
 
3. Kress, G. J. & Mennerick, S. Action potential initiation and propagation: upstream 
influences on neurotransmission. Neuroscience 158, 211–222 (2009). 
4. Katz, B. Neural transmitter release: from quantal secretion to exocytosis and beyond. 
J. Neurocytol. 32, 437–446 (2003). 
5. Rangel-Gomez, M. & Meeter, M. Neurotransmitters and Novelty: A Systematic 
Review. J. Psychopharmacol. (Oxf.) 30, 3–12 (2016). 
6. Nemecz, Á., Prevost, M. S., Menny, A. & Corringer, P.-J. Emerging Molecular 
Mechanisms of Signal Transduction in Pentameric Ligand-Gated Ion Channels. 
Neuron 90, 452–470 (2016). 
7. daCosta, C. J. B. & Baenziger, J. E. Gating of Pentameric Ligand-Gated Ion 
Channels: Structural Insights and Ambiguities. Structure 21, 1271–1283 (2013). 
8. Andrew J Thompson, H. A. L. The structural basis of function in Cys-loop receptors. 
Q. Rev. Biophys. 43, 449–99 (2010). 
9. Dineley, K. T., Pandya, A. A. & Yakel, J. L. Nicotinic ACh Receptors as Therapeutic 
Targets in CNS Disorders. Trends Pharmacol. Sci. 36, 96–108 (2015). 
10. Thompson, A. J. & Lummis, S. C. The 5-HT3 receptor as a therapeutic target. Expert 
Opin. Ther. Targets 11, 527–540 (2007). 
11. Lynch, J. W. Molecular Structure and Function of the Glycine Receptor Chloride 
Channel. Physiol. Rev. 84, 1051–1095 (2004). 
12. Schaefer, N., Roemer, V., Janzen, D. & Villmann, C. Impaired Glycine Receptor 
Trafficking in Neurological Diseases. Front. Mol. Neurosci. 11, (2018). 
13. Greenfield, L. J. Molecular Mechanisms of Antiseizure Drug Activity at GABAA 
Receptors. Seizure J. Br. Epilepsy Assoc. 22, 589–600 (2013). 
14. Nuss, P. Anxiety disorders and GABA neurotransmission: a disturbance of 
modulation. Neuropsychiatr. Dis. Treat. 11, 165–175 (2015). 
15. Palma, E. et al. Modulation of GABAA Receptors in the Treatment of Epilepsy. 
Curr. Pharm. Des. 23, 5563–5568 (2017). 
16. Tomek, S. E., LaCrosse, A. L., Nemirovsky, N. E. & Olive, M. F. NMDA Receptor 
Modulators in the Treatment of Drug Addiction. Pharmaceuticals 6, 251–268 (2013). 
17. Ghasemi, M., Phillips, C., Fahimi, A., McNerney, M. W. & Salehi, A. Mechanisms 
of action and clinical efficacy of NMDA receptor modulators in mood disorders. 
Neurosci. Biobehav. Rev. 80, 555–572 (2017). 
18. Bowie, D. Ionotropic Glutamate Receptors & CNS Disorders. CNS Neurol. Disord. 
Drug Targets 7, 129–143 (2008). 
19. Burnstock, G., Nistri, A., Khakh, B. S. & Giniatullin, R. ATP-gated P2X receptors in 
health and disease. Front. Cell. Neurosci. 8, (2014). 
20. Lee, K. et al. Chapter Six - AMPA Receptors as Therapeutic Targets for 
Neurological Disorders. in Advances in Protein Chemistry and Structural Biology 
(ed. Donev, R.) 103, 203–261 (Academic Press, 2016). 
21. Sharma, G. & Vijayaraghavan, S. Nicotinic Receptors: Role in Addiction and Other 
Disorders of the Brain. Subst. Abuse Res. Treat. 1, 81–95 (2008). 
22. Brunzell, D. H., Stafford, A. M. & Dixon, C. I. Nicotinic receptor contributions to 
smoking: insights from human studies and animal models. Curr. Addict. Rep. 2, 33–
46 (2015). 
23. Vincent, A., Palace, J. & Hilton-Jones, D. Myasthenia gravis. The Lancet 357, 2122–
2128 (2001). 
19 
 
24. Nys, M., Kesters, D. & Ulens, C. Structural insights into Cys-loop receptor function 
and ligand recognition. Biochem. Pharmacol. 86, 1042–1053 (2013). 
25. Corringer, P.-J. et al. Structure and Pharmacology of Pentameric Receptor Channels: 
From Bacteria to Brain. Structure 20, 941–956 (2012). 
26. Albuquerque, E. X., Pereira, E. F. R., Alkondon, M. & Rogers, S. W. Mammalian 
Nicotinic Acetylcholine Receptors: From Structure to Function. Physiol. Rev. 89, 73–
120 (2009). 
27. Lummis, S. C. R. 5-HT3 Receptors. J. Biol. Chem. 287, 40239–40245 (2012). 
28. Sigel, E. & Steinmann, M. E. Structure, Function, and Modulation of GABAA 
Receptors. J. Biol. Chem. 287, 40224–40231 (2012). 
29. Betz, H. & Laube, B. Glycine receptors: recent insights into their structural 
organization and functional diversity. J. Neurochem. 97, 1600–1610 (2006). 
30. Bocquet, N. et al. A prokaryotic proton-gated ion channel from the nicotinic 
acetylcholine receptor family. Nature 445, 116–119 (2007). 
31. Morales-Perez, C. L., Noviello, C. M. & Hibbs, R. E. X-ray structure of the human 
α4β2 nicotinic receptor. Nature 538, 411–415 (2016). 
32. Tasneem, A., Iyer, L. M., Jakobsson, E. & Aravind, L. Identification of the 
prokaryotic ligand-gated ion channels and their implications for the mechanisms and 
origins of animal Cys-loop ion channels. Genome Biol. 6, R4 (2005). 
33. Hilf, R. J. C. & Dutzler, R. X-ray structure of a prokaryotic pentameric ligand-gated 
ion channel. Nature 452, 375–379 (2008). 
34. Jennie M E Cederholm, P. R. S. Gating mechanisms in Cys-loop receptors. Eur. 
Biophys. J. EBJ 39, 37–49 (2009). 
35. Lynagh, T. & Pless, S. A. Principles of agonist recognition in Cys-loop receptors. 
Membr. Physiol. Membr. Biophys. 5, 160 (2014). 
36. Van Arnam, E. B. & Dougherty, D. A. Functional Probes of Drug–Receptor 
Interactions Implicated by Structural Studies: Cys-Loop Receptors Provide a Fertile 
Testing Ground. J. Med. Chem. 57, 6289–6300 (2014). 
37. Xiu, X., Puskar, N. L., Shanata, J. A. P., Lester, H. A. & Dougherty, D. A. Nicotine 
binding to brain receptors requires a strong cation–π interaction. Nature 458, 534–
537 (2009). 
38. Sever, R. & Glass, C. K. Signaling by Nuclear Receptors. Cold Spring Harb. 
Perspect. Biol. 5, (2013). 
39. Yaşar, P., Ayaz, G., User, S. D., Güpür, G. & Muyan, M. Molecular mechanism of 
estrogen–estrogen receptor signaling. Reprod. Med. Biol. 16, 4–20 (2017). 
40. Arnal, J.-F. et al. Membrane and Nuclear Estrogen Receptor Alpha Actions: From 
Tissue Specificity to Medical Implications. Physiol. Rev. 97, 1045–1087 (2017). 
41. Farooq, A. Structural and Functional Diversity of Estrogen Receptor Ligands. Curr. 
Top. Med. Chem. 15, 1372–1384 (2015). 
42. McDonnell, D. P. The molecular determinants of estrogen receptor pharmacology. 
Maturitas 48, 7–12 (2004). 
43. Cheskis, B. J., Greger, J. G., Nagpal, S. & Freedman, L. P. Signaling by estrogens. J. 
Cell. Physiol. 213, 610–617 (2007). 
44. Deroo, B. J. & Korach, K. S. Estrogen receptors and human disease. J. Clin. Invest. 
116, 561–570 (2006). 
20 
 
45. Lim, E. et al. Pushing estrogen receptor around in breast cancer. Endocr. Relat. 
Cancer 23, T227–T241 (2016). 
46. Hua, H., Zhang, H., Kong, Q. & Jiang, Y. Mechanisms for estrogen receptor 
expression in human cancer. Exp. Hematol. Oncol. 7, 24 (2018). 
47. Rothenberger, N. J., Somasundaram, A. & Stabile, L. P. The Role of the Estrogen 
Pathway in the Tumor Microenvironment. Int. J. Mol. Sci. 19, (2018). 
48. Jameera Begam, A., Jubie, S. & Nanjan, M. J. Estrogen receptor agonists/antagonists 
in breast cancer therapy: A critical review. Bioorganic Chem. 71, 257–274 (2017). 
49. Patel, H. K. & Bihani, T. Selective estrogen receptor modulators (SERMs) and 
selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol. Ther. 
186, 1–24 (2018). 
50. Heery, M., Corbett, P. & Zelkowitz, R. Precautions for Patients Taking Tamoxifen. J. 
Adv. Pract. Oncol. 9, 78–83 (2018). 
51. Robinson-Rechavi, M., Garcia, H. E. & Laudet, V. The nuclear receptor superfamily. 
J. Cell Sci. 116, 585–586 (2003). 
52. Heldring, N. et al. Estrogen Receptors: How Do They Signal and What Are Their 
Targets. Physiol. Rev. 87, 905–931 (2007). 
53. Parker, M. G. Structure and Function of Estrogen Receptors. in Vitamins & 
Hormones (ed. Litwack, G.) 51, 267–287 (Academic Press, 1995). 
54. Kumar, R. et al. The Dynamic Structure of the Estrogen Receptor. Journal of Amino 
Acids (2011). doi:10.4061/2011/812540 
55. Norris, J. D., Chang, C. & McDonnell, D. P. Estrogen receptor-cofactor interactions 
as targets for novel drug discovery. Ernst Scher. Res. Found. Workshop 181–201 
(2001). 
56. Atsriku, C. et al. Systematic Mapping of Posttranslational Modifications in Human 
Estrogen Receptor-α with Emphasis on Novel Phosphorylation Sites. Mol. Cell. 
Proteomics MCP 8, 467–480 (2009). 
57. Anbalagan, M., Huderson, B., Murphy, L. & Rowan, B. G. Post-translational 
modifications of nuclear receptors and human disease. Nucl. Recept. Signal. 10, 
(2012). 
58. Merrell, K. W. et al. Differential recruitment of nuclear receptor coregulators in 
ligand-dependent transcriptional repression by estrogen receptor-α. Oncogene 30, 
1608–1614 (2011). 
59. Tremblay, G. B. & Giguère, V. Coregulators of estrogen receptor action. Crit. Rev. 
Eukaryot. Gene Expr. 12, 1–22 (2002). 
60. Manavathi, B., Samanthapudi, V. S. K. & Gajulapalli, V. N. R. Estrogen receptor 
coregulators and pioneer factors: the orchestrators of mammary gland cell fate and 
development. Front. Cell Dev. Biol. 2, (2014). 
61. Leisle, L., Valiyaveetil, F., Mehl, R. A. & Ahern, C. A. Incorporation of non-
canonical amino acids. Adv. Exp. Med. Biol. 869, 119–151 (2015). 
62. Dougherty, D. A. & Van Arnam, E. B. In Vivo Incorporation of Unnatural Amino 
Acids Using the Chemical Aminoacylation Strategy. A Broadly Applicable 
Mechanistic Tool. Chembiochem Eur. J. Chem. Biol. 15, 1710–1720 (2014). 
63. Nowak, M. W. et al. [28] In vivo incorporation of unnatural amino acids into ion 
channels in Xenopus oocyte expression system. in (ed. Enzymology, B.-M. in) 293, 
504–529 (Academic Press, 1998). 
21 
 
64. Noren, C. J., Anthony-Cahill, S. J., Griffith, M. C. & Schultz, P. G. A general method 
for site-specific incorporation of unnatural amino acids into proteins. Science 244, 
182–188 (1989). 
65. Liu, C. C. & Schultz, P. G. Adding New Chemistries to the Genetic Code. Annu. Rev. 
Biochem. 79, 413–444 (2010). 
66. Papke, R. L. & Smith-Maxwell, C. High-throughput electrophysiology with Xenopus 
oocytes. Comb. Chem. High Throughput Screen. 12, 38–50 (2009). 
67. Colquhoun, D. Binding, gating, affinity and efficacy: The interpretation of structure-
activity relationships for agonists and of the effects of mutating receptors. Br. J. 
Pharmacol. 125, 923–947 (1998). 
68. Horovitz, A. Double-mutant cycles: a powerful tool for analyzing protein structure 
and function. Fold. Des. 1, R121–R126 (1996). 
69. Shanata, J. A. P., Frazier, S. J., Lester, H. A. & Dougherty, D. A. Using Mutant 
Cycle Analysis to Elucidate Long-Range Functional Coupling in Allosteric 
Receptors. Methods Mol. Biol. Clifton NJ 796, 97–113 (2012). 
70. Miles, T. F., Bower, K. S., Lester, H. A. & Dougherty, D. A. A Coupled Array of 
Noncovalent Interactions Impacts the Function of the 5-HT3A Serotonin Receptor in 
an Agonist-Specific Way. ACS Chem. Neurosci. 3, 753–760 (2012). 
71. Modell, A. E., Blosser, S. L. & Arora, P. S. Systematic Targeting of Protein–Protein 
Interactions. Trends Pharmacol. Sci. 37, 702–713 (2016). 
72. Jin, L., Wang, W. & Fang, G. Targeting Protein-Protein Interaction by Small 
Molecules. Annu. Rev. Pharmacol. Toxicol. 54, 435–456 (2014). 
73. Scott, D. E., Bayly, A. R., Abell, C. & Skidmore, J. Small molecules, big targets: 
drug discovery faces the protein–protein interaction challenge. Nat. Rev. Drug 
Discov. 15, 533–550 (2016). 
74. Coin, I. Application of non-canonical crosslinking amino acids to study protein–
protein interactions in live cells. Curr. Opin. Chem. Biol. 46, 156–163 (2018). 
75. Tanaka, Y., Bond, M. R. & Kohler, J. J. Photocrosslinkers illuminate interactions in 
living cells. Mol. Biosyst. 4, 473–480 (2008). 
76. O’Reilly, F. J. & Rappsilber, J. Cross-linking mass spectrometry: methods and 
applications in structural, molecular and systems biology. Nat. Struct. Mol. Biol. 25, 
1000 (2018). 
77. Sinz, A. Cross-Linking/Mass Spectrometry for Studying Protein Structures and 
Protein–Protein Interactions: Where Are We Now and Where Should We Go from 
Here? Angew. Chem. Int. Ed. 57, 6390–6396 (2018). 
78. Chin, J. W. & Schultz, P. G. In Vivo Photocrosslinking with Unnatural Amino Acid 
Mutagenesis. ChemBioChem 3, 1135–1137 (2002). 
 
22 
 
 
Chapter 2: A triad of residues is functionally transferrable between 5-
HT3 serotonin receptors and nicotinic acetylcholine receptors*
 
2.1 Abstract 
Cys-loop receptors are pentameric ligand-gated ion channels that facilitate 
communication within the nervous system. Upon ligand binding, these receptors undergo 
an allosteric activation mechanism connecting the binding event to the membrane-spanning 
channel pore, which expands to conduct ions. Some of the earliest steps in this activation 
mechanism are carried out by residues proximal to the binding site, the relative positioning 
of which may reflect functional differences among the receptors. Herein, we investigated 
key side-chain interactions near the binding site via mutagenesis and two-electrode 
voltage-clamp electrophysiology in serotonin-gated 5-HT3A receptors (5-HT3ARs) and 
nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus laevis oocytes. We 
found that a triad of residues aligning to Thr-152, Glu-209, and Lys-211 in the 5-HT3AR 
can be exchanged between the homomeric 5-HT3AR and the muscle-type nAChR α-subunit 
with small functional consequences. Via triple mutant cycle analysis, we demonstrated that 
this triad forms an interdependent network in the muscle-type nAChR. Further, nAChR-
type mutations of the 5-HT3AR affect the affinity of nicotine, a competitive antagonist of 
5-HT3ARs, in a cooperative manner. Using mutant cycle analyses between the 5-HT3A triad, 
                                                     
* This chapter is adapted with permission from: Mosesso, R. & Dougherty, D. A. A triad 
of residues is functionally transferrable between 5-HT3 serotonin receptors and nicotinic 
acetylcholine receptors. J. Biol. Chem. 293, 2903–2914 (2018). 
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loop A residues Asn-101 and Glu-102, ß9 residue Lys-197, and the channel gate at Thr-
257, we observed that residues in this region are energetically linked to the channel gate 
and are particularly sensitive to mutations that introduce a net positive charge. This study 
expands our understanding of the differences and similarities in the activation mechanisms 
of Cys-loop receptors. 
2.2 Introduction 
Cys-loop receptors are the subset of pentameric ligand-gated ion channels found in 
vertebrates, and include excitatory nicotinic acetylcholine receptors (nAChRs) and 
serotonin-activated 5-HT3 receptors (5-HT3Rs), as well as inhibitory type A γ-
aminobutyric acid receptors (GABAARs), and glycine receptors (GlyRs).
1–4 The 
pharmacology of these receptors is quite broad, and targeted therapeutics may lead to novel 
treatments for a variety of conditions.5–7 
The overall structure of Cys-loop receptors is highly conserved.8 Each subunit is 
composed of an extracellular domain (ECD) beta sandwich, a transmembrane domain 
(TMD) formed by four α-helices (numbered M1-M4), and a variable intracellular domain 
defined primarily by the loop between the M3 and M4 helices. Five subunits assemble in 
a concentric manner to form a single receptor. Ligand binding sites are formed at subunit 
interfaces in the ECD by three primary (+) face “loops” A-C, and three complementary (-
) face “loops” D-F. An overall picture of the 5-HT3R and the interface between two 
subunits, as exemplified in a cryo-EM structure of the homopentameric 5-HT3AR, is shown 
in Figure 2.1A (PDB ID: 6HIO).9  
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The advent of complete structures of eukaryotic Cys-loop receptors, while 
generally at fairly low resolution, has provided valuable guidance for comparing members 
of the Cys-loop receptor family. The present work was motivated by the recognition of a 
 
Figure 2.1. Region of interest in this study. A, View of two adjacent receptor subunits 
from the 5-HT3AR cryo-EM (PDB 6HIO), with 5-HT shown as spheres (left). Yellow, 
carbon atoms of residues mutated in this study; pink, serotonin carbon atoms; black, 
aromatic box carbon atoms; blue, nitrogen atoms; red, oxygen atoms. B, Sequence 
alignment of subunits contributing to the primary binding face of human-type 5-
HT3ARs, nAChRs, and GABAARs. Cells are colored according to side-chain chemistry. 
Unfilled cells indicate non-conservation with regard to the triad in that receptor 
subtype. ECD, extracellular domain; TMD, transmembrane domain; ICD, intracellular 
domain, was excluded from this figure. *Residue numbers corresponding to the 5-
HT3AR cryo-EM structure (PDB: 6HIO).  
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triad of residues that are, in a global sense, conserved across several members of the family. 
Our primary focus has been on the homopentameric 5-HT3AR, for which the residues of 
interest are T152, E209, and K211 (numbering as in the crystal structure10 and cryo-EM 
structures;9,11,12 these have been referred to elsewhere at T179, E236, and K238). The 
aligning residues in the nAChR α-subunits are typically K, D, and T, respectively, while 
those in the GABAAR ß-subunits are E, R, and S, respectively. Thus, in each triad, there is 
a cationic residue (K/R), an anionic residue (D/E), and a residue with an alcohol side chain 
(S/T), however the relative positioning of these functionalities varies among these 
receptors. This curious observation led us to ask whether the arrangement reflects 
differences among receptors. A sequence alignment (Figure 2.1B) illustrates the 
conservation of these arrangements within individual receptor subfamilies in humans. Note 
that there are exceptions in the α5 and α10 nAChR subunits, however these particular α-
subunits do not contribute to the primary binding face of nAChRs.1 The α8 nAChR subunit 
was excluded because it is not found in mammals.1 
Herein we evaluate the functional role of this triad in two excitatory Cys-loop 
receptors – the 5-HT3AR and the muscle-type ((α1)2ß1γδ) nAChR – using two-electrode 
voltage clamp electrophysiology of mutant receptors expressed in Xenopus laevis oocytes. 
We find that the 5-HT3AR and nAChR triads can be swapped between these two receptors 
with only small losses of function. Additionally, substituting the nAChR triad into the 5-
HT3AR increases the affinity of nicotine, demonstrating that this triad influences ligand 
binding. In contrast, swapping the triad from the inhibitory GABAAR into the 5-HT3AR 
does not result in a functional receptor.  
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We note from the start that several of the residues considered here have been 
evaluated by other investigators, and we have built off that work. In muscle-type nAChRs, 
state-dependent interactions have been proposed between K145, D200, and Y190.13–18 The 
former two residues are part of the above-described “triad,” and Y190 sits on loop C and 
is part of the aromatic box that contributes to the agonist binding site.19,20 The key hydrogen 
bonding role proposed for Y190, however, is not possible in the 5-HT3AR, as the aligning 
residue is F199. As described below, a more general interaction between the 5-HT3R triad 
and loop A of the agonist binding site is seen. Overall, these results highlight similarities 
and variations across members of the Cys-loop family. 
2.3 Results and Discussion 
2.3.1 Effects of exchanging triads between the 5-HT3AR and the muscle-type nAChR 
To evaluate the role of the triad of residues, we used site-directed mutagenesis to 
introduce mutations into receptors expressed in Xenopus laevis oocytes and measured 
functional responses via dose-response relationships using two-electrode voltage clamp 
electrophysiology, as described in Experimental Procedures. We generated the 5-HT3AR 
single mutants T152K, E209D and K211T, (corresponding to the aligning nAChR 
residues) as well at the double mutants T152K/K211T, E209D/K211T, and T152K/K211T 
and the triple mutant T152K/E209D/K211T. The average dose-response curves measured 
for these mutant receptors are compared in Figure 2.2A, and the full pharmacological 
characterization in response to the native agonist serotonin (5-hydroxytryptamine, or 5-
HT) is provided in Table 2.1. Relative to the wild-type 5-HT3AR, the single mutant 
receptors had EC50 values for serotonin that were 39-, 10-, and 1.2-fold greater than wild-
type for T152K, E209D, and K211T, respectively. While the losses of function for T152K 
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and E209D are clearly meaningful, the consequence K211T is not. Note that structurally, 
however, the E209D mutation would be expected to be the least perturbing. 
Next, double mutants incorporating each of the above three mutations in pairs were 
generated in order to 
evaluate energetic 
coupling between the 
mutations via mutant 
cycle analyses. The 
extent of energetic 
coupling in a mutant 
cycle analysis is 
defined as the ∆∆G° 
value for the double 
mutant, and quantifies 
the extent to which the 
individual mutations 
cooperate in the 
activation mechanism 
of the receptor.21 If 
residues are close 
enough in space that a 
direct interaction is 
 
Figure 2.2. Mutating residues T152, E209, and K211 in 5-
HT3ARs to their equivalents in nAChRs has non-additive 
effects on receptor function. A, Dose-response curves of 
wild-type and mutant receptors to 5-HT. Variants are ordered 
from top to bottom in order of increasing EC50. B, Scatterplots 
illustrating losses of function (±S.D.) of mutants on a 
logarithmic scale. The double mutants and triple mutant 
display considerable deviations from additivity.   
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possible, the ∆∆G° value can also be used as a readout of the strength of this interaction.  
The results of the double mutant cycles are provided in Table 2.1. Figure 2.2B 
illustrates the non-additive effects of the mutations as a scatterplot. The T152K/K211T 
double-mutant had an EC50 of only 2.5 ± 0.05µM 5-HT, a mere 2-fold loss of function 
relative to wild-type (1.3 ± 0.03µM) and a 19-fold gain of function relative to the single 
mutant T152K (EC50 = 49 ± 1.03µM). Thus, these two mutations are strongly energetically 
coupled, with ∆∆G° = 1.8 kcal•mol-1. This and their close orientation in space suggest a 
direct interaction between these two residues. The double mutant E209D/K211T showed a 
much lower coupling energy of ∆∆G° = 0.49 kcal•mol-1. We consider a two-fold deviation 
from additivity (∆∆G° ≥ 0.40 kcal•mol-1) to be meaningful, suggesting that the E209D and 
K211T mutations do affect one another, albeit much less so than the T152K/K211T double 
mutant.  
The double mutant T152K/E209D was nonfunctional up to 800µM 5-HT. If the 
effects of the two mutations were additive, one would expect an EC50 on the order of 
~500µM 5-HT. If this were the case, we unfortunately could not measure a full dose-
Table 2.1 
Response to 5-HT of 5-HT
3A
Rs incorporating nAChR-type mutations. 
 
†
kcal•mol
-1
; *Measured in the background of K211T; NR = no response; ± indicates 
SEM. 
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response relationship due to open channel block of 5-HT3ARs at high concentrations of 5-
HT. In order to meet our criterion for a meaningful coupling energy of ≥ 0.40 kcal•mol-1, 
the EC50 would either have to be less than ~200µM 5-HT if the mutations are meaningfully 
sub-additive or greater than ~800µM 5-HT if they are superadditive. The two mutations 
are clearly not sub-additive, as we observed no response to concentrations of 5-HT up to 
800µM. It remains possible that the effects of these mutations are superadditive, i.e. the 
deleterious effects of the mutations are augmented when both are included together. It is 
also possible that combining the T152K and E209D mutations impairs proper folding or 
trafficking of receptors to the cell surface, as we did not control for this possibility.  
Having generated the single mutants and double mutants, we next generated the 5-
HT3AR variant T152K/E209D/K211T, incorporating all three residues of the nicotinic 
triad. This receptor had only an 8.4-fold increase in 5-HT EC50 relative to wild type, 
comparable to the single-mutant E209D and much less than the single-mutant T152K. The 
increase in EC50 for the triple mutant is much less than would be expected if the effects of 
three mutations were additive. Thus, the full three-residue swap of nAChR residues into 
the 5-HT3AR produces functional receptors.  
Having the triple mutant enables a mutant cycle between T152K and E209D in the 
background of the K211T mutation. This mutant cycle has a ∆∆G° = 0.04 kcal•mol-1 
(Table 2.1), suggesting that T152K and E209D affect the receptor in distinct ways, at least 
in the background of K211T. The triple mutant also had somewhat different apparent 
activation/deactivation kinetics than wild-type receptors, and a greater extent of open 
channel block at concentrations of 5-HT above those that caused a maximal response.  
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We next tested to see how a prototypical nAChR, the muscle-type ((α1)2ß1γδ) 
nAChR, would respond when the 5-HT3AR triad was introduced. While the most recent 
nAChR structural data are for the α4ß2 neuronal subtype,22,23 we were unable to perform 
the desired experiments in that subtype due to poor expression levels. This can be addressed 
by introducing mutations to the channel pore residue L9’ that enhance gating of nAChRs 
in a general way,24–26 however this would complicate our analysis as the residues of interest 
are involved in receptor gating. However, the muscle-type nAChR expresses robustly in 
Xenopus oocytes. The relevant residues are the same in the α1 (muscle-type) and α4 
subunits, and they are positioned similarly in the cryo-EM structure of the highly 
homologous Torpedo receptor (PDB ID: 2BG9).27 We generated single mutants α1 K145T, 
D200E, and T202K, and the pharmacological responses of these mutants to the native 
agonist acetylcholine (ACh) are summarized in Table 2.2. Dose-response relationships and 
scatterplots of log(fold-shift) values for individual runs are compared between the mutant 
receptors and wild-type in Figure 2.3A and 2.3B, respectively. All single mutations caused 
modest losses of function:  4.9-, 2.9-, and 9.0-fold for K145T, D200E, and T202K, 
respectively.  
Table 2.2 
Response to ACh of muscle-type nAChRs incorporating 5-HT
3A
R-type mutations. 
 
†
kcal•mol
-1
; ± indicates SEM. 
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We next generated double mutant pairs in the nAChR (Table 2.2) as described 
previously for the 5-HT3AR. 
Interestingly, the ∆∆G° 
values for each of the double 
mutants K145T/D200E, 
D200E/T202K, and 
K145T/T202K were all near 
1.0 kcal•mol-1, indicating a 
similar degree of 
cooperativity between any 
two mutations. It is not 
surprising that mutations to 
K145 and D200 should be 
coupled, as previous work has 
proposed a salt bridge 
between these residues in the 
muscle-type nAChR.13 
Indeed, analysis via patch 
clamp electrophysiology of 
the steady-state dissociation 
of ACh from the double 
mutant K145Q D200N has 
been previously observed to 
 
Figure 2.3. Mutating muscle-type nAChR residues 
K145, D200, and T202 to their equivalents in 5-
HT3ARs has non-additive effects on receptor 
function. A, Dose-response curves of wild-type and 
mutant receptors to ACh. B, Scatterplots illustrating 
losses of function (±S.D.) of mutants on a logarithmic 
scale. The double mutants and triple mutant display 
considerable deviations from additivity.   
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give a very similar ∆∆G° value of 1.0 kcal•mol-1, and other measures suggest a strong 
interaction between the two.13  Our observation that both residues also couple to T202 
suggests interactions among all three. 
The next logical step was to evaluate the functional response to ACh of the triple 
mutant:  α1 K145T/D200E/T202K. The triple mutant receptor was functional, with EC50 = 
67 ± 5.3µM ACh, a 4.3-fold increase from wild-type (Table 2.2). The data from the single, 
double, and triple mutants enables a triple mutant cycle analysis of these three mutations. 
A triple mutant cycle can be represented as a cube (Figure 2.4), with the difference 
between each opposite face giving a ∆∆∆G°, which quantifies the interaction energy 
among all three 
residues as a unit.28 
We find in each case 
that ∆∆∆G° = 0.95 
kcal•mol-1. That is, 
any pair of mutations 
gives ∆∆G° ≈ 0.95 
kcal•mol-1, but in the 
background of any 
single mutation a 
double mutant cycle 
of the other two 
mutations yields 
∆∆G° ≈ 0 kcal•mol-1. 
 
Figure 2.4. Triple mutant cycle in the muscle-type nAChR. 
Each face of the cube represents a double mutant cycle. Double 
mutant cycles from wild-type are meaningfully coupled, 
however any pair of mutations is uncoupled in the background 
of the other mutation of the triad. This analysis yields G = 
0.95 kcal•mol-1 for the three mutations. 
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Thus, these residues not only interact with one another in the activation mechanism, but 
operate as a co-dependent unit in the mouse muscle-type nAChR. Each pair of residues is 
energetically dependent on the third residue of the triad.  
To further evaluate the role of this triad, we mutated residues in the 5-HT3AR to 
their equivalents in GABAAR ß-subunits, which form the primary binding face in 
GABAARs. The results are summarized in Table 2.3. The single-mutant T152E showed a 
10-fold loss of function, while the mutation K211S had no functional consequence. The 
single-mutant E209R, however, was nonfunctional up to 800µM 5-HT. Attempts to 
transplant the entire GABAAR triad into the 5-HT3AR – T152E/E209R/K211S – yielded 
no observable response to concentrations of 5-HT as high as 800µM. Thus, the triad of 
GABAARs appears to behave differently than that of the excitatory 5-HT3AR. It is also 
possible, however, that the receptor mutants that did not appear to respond to 5-HT were 
not expressing or not reaching the cell surface.  
2.3.2 Mutating the 5-HT3AR triad to that of the nAChR increases the binding affinity of 
nicotine 
Table 2.3 
Response to 5-HT of 5-HT3ARs incorporating GABAAR-type mutations. 
Mutation(s) EC50 (µM) nH |Imax| (μA) Fold N 
- 1.3 ± 0.03 2.4 ± 0.11 1.0 - 78 1.0 21 
T152E 13 ± 0.37 1.8 ± 0.08 0.25 - 3.6 10 15 
E209R NR NR NR NR 12 
K211S 1.3 ± 0.05 2.1 ± 0.14 5.0 - 47 1.1 15 
T152E E209R NR NR NR NR 8 
T152E K211S NE NE NE NE 0 
E209R K211S NR NR NR NR 12 
T152E E209R K211S NR NR NR NR 4 
†
kcal•mol
-1
; NR = no response; NE = not established; ± indicates SEM. 
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Having established that 5-HT3ARs incorporating the nAChR-type triad are 
functional, we next evaluated whether residues in the 5-HT3AR triad contribute to the 
 
Figure 2.5. Dose-response curves of 5-HT3AR variants in the presence of varying 
concentrations of nicotine. As a competitive antagonist, nicotine shifts the dose-
response curve of 5-HT3ARs to higher EC50 values. Some variants are more sensitive to 
competitive inhibition by nicotine than others. 
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pharmacological properties of nicotine, an agonist of most neuronal nAChRs and a 
competitive antagonist of 5-
HT3ARs.
1,29 To accomplish this, we 
again expressed mutant 5-HT3ARs 
incorporating the nicotinic-type 
mutations T152K, E209D, and K211T 
as single, double, and triple mutants in 
Xenopus laevis oocytes, and generated 
Schild plots for each receptor 
variant.30,31 In this procedure, dose-
response relationships of each receptor 
variant were measured in the presence 
of different concentrations of nicotine. 
Higher concentrations of nicotine 
progressively increase the EC50 of 5-
HT as nicotine displaces 5-HT in the 
orthosteric binding site (Figure 2.5). 
In a Schild plot, the x-intercept gives a 
readout of the equilibrium dissociation 
constant (Kd) for the antagonist.
30,31  
The Schild plots for each 
variant are compared to that of the 
wild-type nAChR in Figure 2.6, the 
 
Figure 2.6. Schild analysis of inhibition of 5-
HT3ARs by nicotine. Schild plots of A, single 
mutant, B, double mutant, and C, triple mutant 
5-HT3ARs with nAChR-type substitutions. 
Meaningful changes in nicotine Kd are observed, 
and the mutations have non-additive effects. 
Error bars are shown as S.E.M., and are often 
smaller than the data points.  
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parameters of the linear fits are provided in Table 2.4, and the full pharmacological 
characterization of the nicotine inhibition experiments is provided in Table 2.5. The single 
mutants T152K, E209D, and K211T increased the Kd of nicotine by 1.5-, 13-, and 2.5-fold, 
respectively.  
Meaningful non-additive effects are observed when the mutations are combined in 
the double mutants and the triple mutant. Despite T152K and K211T each producing small 
increases in the Kd of nicotine, the double-mutant T152K/K211T is 2.2-fold more sensitive 
to nicotine than wild-type. The double mutant E209D/K211T is more sensitive to inhibition 
by nicotine than E209D on its own, even though K211T increases the Kd of nicotine on its 
own. The triple mutant is the most nicotine-sensitive of all the variants, with a Kd 5-fold 
lower than that of wild-type. Thus these three residues influence the binding of nicotine to 
the 5-HT3AR. In particular, rearranging the side-chain groups T152 and K211 to their 
respective positions in nAChRs generates variants that are more sensitive to nicotine 
inhibition than wild-type. The mutation E209D, while causing a sizable decrease in 
nicotine affinity on its own, gives further increase in nicotine sensitivity when combined 
with T152K and K211T in the triple mutant receptor.  
Table 2.4 
Schild fit parameters for 5-HT3AR variants.  
 
*measured in the background of K211T. 
Mutation(s) Slope R
2
Kd (µM) Fold G (kcal•mol
-1
)
wild-type 0.94 ± 0.07 0.97 12 ± 3.4 1.0 -
T152K 1.0 ± 0.17 0.93 18 ± 4.7 1.5 -
E209D 1.3 ± 0.18 0.96 160 ± 84 13 -
K211T 1.07 ± 0.16 0.94 31 ± 8.2 2.5 -
T152K K211T 1.1 ± 0.04 >0.99 5.7 ± 0.85 0.46 1.1
E209D K211T 0.78 ± 0.15 0.90 91 ± 49 7.4 0.60
T152K E209D K211T 0.88 ± 0.06 0.98 2.6 ± 0.78 0.21 1.2*
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All this together suggests intimate cooperativity between these three residues in 
regard to nicotine binding. Mutant cycles of nicotine Kd values (Table 2.4) yield 
meaningful coupling energies for all pairs of mutations: 1.1kcal•mol-1 for T152K and 
K211T, 0.60kcal•mol-1 for E209D and K211T, and 1.2kcal•mol-1 for T152K and E209D in 
the background of K211T.  
 
Table 2.5
Mutation(s) [Nicotine] (µM) EC50 (µM) nH |Imax| (µA) Fold N
wt 0 1.3 ± 0.03 2.4 ± 0.11 1.0 - 78 1.0 21
wt 2.5 1.5 ± 0.02 4.0 ± 0.13 0.68 - 7.4 1.2 14
wt 7.5 2.3 ± 0.06 5.0 ± 0.61 0.99 - 4.8 1.8 8
wt 25 3.7 ± 0.06 3.0 ± 0.12 0.50 - 4.4 2.9 14
wt 75 7.6 ± 0.22 2.5 ± 0.16 1.1 - 10 6.0 15
wt 250 15 ± 0.38 3.1 ± 0.20 1.7 - 4.4 12 7
wt 350 24 ± 0.77 2.6 ± 0.20 0.20 - 3.1 19 6
wt 1000 143 ± 5.9 3.3 ± 0.38 0.41 - 2.8 110 6
T152K 0 49 ± 1.0 1.9 ± 0.06 0.14 - 11 1.0 15
T152K 7.5 71 ± 1.7 2.1 ± 0.08 1.9 - 7.0 1.5 6
T152K 15 95 ± 2.5 2.1 ± 0.09 3.0 - 17 1.9 8
T152K 25 92 ± 2.3 2.4 ± 0.11 0.59 - 5.9 1.9 7
T152K 50 219 ± 13 2.4 ± 0.28 0.81 - 5.6 4.5 8
T152K 75 284 ± 9.1 2.4 ± 0.16 0.60 - 11 5.8 10
E209D 0 13 ± 0.21 2.2 ± 0.07 0.53 - 20 1.0 15
E209D 50 16 ± 0.29 2.6 ± 0.10 0.65 - 11 1.3 8
E209D 75 29 ± 1.0 1.8 ± 0.10 2.1 - 2.9 2.2 2
E209D 250 31 ± 1.1 2.7 ± 0.21 0.41 - 3.2 2.4 7
E209D 350 58 ± 1.4 2.4 ± 0.12 1.4 - 4.2 4.5 3
K211T 0 1.5 ± 0.04 2.5 ± 0.16 1.9 - 25 1.0 15
K211T 25 2.7 ± 0.05 2.8 ± 0.14 6.0 - 17 1.8 7
K211T 50 5.6 ± 0.12 2.3 ± 0.10 1.9 - 4.7 3.8 8
K211T 75 5.1 ± 0.07 2.7 ± 0.09 3.6 - 12 3.5 5
K211T 250 14 ± 0.30 2.6 ± 0.13 0.30 - 4.1 9.4 8
K211T 350 21 ± 0.72 2.5 ± 0.18 1.7 - 6.1 14 5
T152K K211T 0 2.5 ± 0.05 2.1 ± 0.08 1.3 - 56 1.0 14
T152K K211T 2.5 3.7 ± 0.11 2.7 ± 0.18 0.84 - 4.8 1.5 8
T152K K211T 7.5 5.6 ± 0.11 2.0 ± 0.07 9.7 - 38 2.2 4
T152K K211T 25 14 ± 0.32 2.9 ± 0.15 0.15 - 58 5.6 7
T152K K211T 75 45 ± 1.9 1.8 ± 0.12 22 - 46 18 4
T152K K211T 250 198 ± 3.0 2.7 ± 0.10 8.8 - 61 79 7
E209D K211T 0 6.9 ± 0.25 2.1 ± 0.11 0.18 - 12 1.0 16
E209D K211T 25 8.9 ± 0.50 1.7 ± 0.13 5.6 - 19 1.3 6
E209D K211T 50 13 ± 0.41 1.9 ± 0.09 1.5 - 5.7 1.9 8
E209D K211T 75 13 ± 0.41 2.0 ± 0.10 4.5 - 16 1.8 6
E209D K211T 250 18 ± 0.64 2.3 ± 0.16 0.74 - 3.1 2.6 7
E209D K211T 350 31 ± 1.8 2.4 ± 0.29 0.58 - 2.52 4.5 5
T152K E209D K211T 0 11 ± 0.39 2.4 ± 0.18 0.15 - 19 1.0 12
T152K E209D K211T 0.25 12 ± 0.17 2.2 ± 0.19 4.4 - 13 1.2 6
T152K E209D K211T 2.5 20 ± 0.41 1.9 ± 0.14 1.4 - 5.3 1.9 7
T152K E209D K211T 7.5 29 ± 1.2 1.9 ± 0.12 1.6 - 16 2.7 7
T152K E209D K211T 25 93 ± 3.8 2.9 ± 0.18 0.80 - 2.9 8.9 7
T152K E209D K211T 75 267 ± 15 2.8 ± 0.31 0.33 - 2.67 25 6
Response to 5-HT of 5-HT3ARs in the presence of varying concentrations of (-)-nicotine.
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We attempted to measure inhibition by 5-HT of muscle-type nAChRs containing 
the 5-HT3AR-type triad. However, the results suggested that 5-HT inhibits both wild-type 
and triple-mutant muscle-type nAChRs via a noncompetitive mechanism, consistent with 
previous work.32 Maximal currents in the presence of 5-HT were decreased, but EC50’s of 
ACh were relatively unchanged (Figure 2.7).  
2.3.3 The 5-HT3AR triad is functionally coupled to nearby residues and the channel gate 
Previous work13 in the muscle-type nAChR identified state-dependent interactions 
critical for initiation of receptor gating between triad residues K145 and D200 and the loop 
C residue Y190, a completely conserved contributor to the aromatic box.33 Structural work 
in related nAChRs (in which this K/D/Y triad is conserved) has supported the conclusions 
of this early experimental work.22,23,27 However, the same set of interactions is clearly not 
present in the 5-HT3AR, as the residue aligning to α1 Y190 in the muscle-type nAChR is a 
 
Figure 2.7. Noncompetitive inhibition by 5-HT of ACh-evoked currents in the 
muscle-type nAChR. Minimal changes occur in ACh EC50 while maximal currents 
are sharply reduced at high [5-HT]. Each dose-response curve was performed on 
different oocytes from the same batch of oocytes injected with the same amount of 
mRNA from the same preparation of mRNA.  The first four (lowest-concentration 
ACh) data points on the 1000µM 5-HT curve were never actually measured, but 
inferred for the purpose of fitting the Hill equation. Error bars represent SEM.  
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phenylalanine residue in the 5-HT3AR. Recent 5-HT3AR structures do, however, suggest 
that there may be interactions between the triad residues examined herein and residues on 
loop A, one of the canonical binding-site loops.9–12  
We have probed for interactions between the 5-HT3AR triad and loop A residues 
N101 and E102 using mutagenesis. For these studies we typically used more conservative 
mutations than were used in the “triad swapping” experiments. For residues E102 and 
E209, we employ mutations to glutamine and/or aspartate; the E102D mutation was not 
examined as it has been observed previously that this mutation has little effect on the 
response of receptors to 5-HT.28 We employ a more drastic mutation at N101, N101K. This 
was motivated by previous work that demonstrated a high loss of function for the N101K 
mutation.34 For mutant cycles with T152, we use the conservative T152V mutation. 
Table 2.6 provides the full characterization of the pharmacological response of 
these receptors to 5-HT. There is extensive crosstalk between the triad and the residues on 
loop A. All triad residues couple to N101, and K211 couples to E102. Figure 2.8 provides 
a visual depiction of the largest coupling energies observed for pairs of mutations at the 
sites shown, including those discussed previously and those discussed hereafter. The ∆∆G° 
values for different mutant cycles in Figure 2.8 are grouped into five categories, each 
representing an additional two-fold deviation from additivity.  
Previous work in the 5-HT3AR on loop A residues N101 and E102 showed that 
mutations to these residues that introduce a net positive charge (N101K and E102Q) 
generate very large losses of function.28,34 This parallels our observation on the T152K 
mutation, which is the most disruptive of the single mutations in the triad swap. We also 
observed a large loss of function for E209Q, which likewise introduces a net positive 
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charge. In contrast, both K211T and K211M, mutations that remove a positive charge, have 
minimal impacts on function, but K211T rescued function of receptors with T152K.  
Table 2.6       
Functional cooperation between triad residues, loop A, K197 (loop C), and the channel gate in mutant  
5-HT3ARs. Table is divided into four sections, from top to bottom: 1. Single mutants, 2. Mutant cycles to  
N101K and T152V, 3.  Mutant cycles examining role of positive charge, 4. Nonresponsive variants. 
Mutation(s) EC50 (µM) nH |Imax| (μA) Fold N ΔΔG† 
- 1.3 ± 0.03 2.4 ± 0.11 1.0 - 78 1.0 21 - 
N101K 42 ± 1.1 2.4 ± 0.11 0.05 - 5.2 34 14 - 
E102Q 85 ± 3.0 1.6 ± 0.07 0.53 - 5.5 68 15 - 
T152V 8.5 ± 0.27 2.2 ± 0.13 0.42 - 78 6.8 11 - 
T152K 49 ± 1.0 1.9 ± 0.06 0.14 - 11 39 15 - 
K197M 1.5 ± 0.04 2.7 ± 0.19 2.1 - 20 1.2 10 - 
E209D 13 ± 0.20 2.3 ± 0.07 0.53 - 20 10 15 - 
E209Q 93 ± 4.3 2.4 ± 0.21 2.0 - 42 75 22 - 
K211M 2.2 ± 0.05 2.9 ± 0.13 4.9 - 15 1.8 9 - 
K211T 1.5 ± 0.04 2.5 ± 0.16 1.9 - 25 1.2 15 - 
N101K T152V 84 ± 4.0 1.8 ± 0.10 7.2 - 17 67 16 0.72 
N101K E209D 29 ± 0.17 2.9 ± 0.04 6.7 - 59 23 17 1.6 
T152V E209D 12 ± 0.21 1.8 ± 0.05 11 - 23 9.5 13 1.1 
T152V E209Q 96 ± 1.5 2.6 ± 0.09 6.1 - 87 76 16 1.0 
N101K K211M 16 ± 0.31 2.0 ± 0.08 0.15 - 5.5 13 13 0.91 
N101K K211T 15 ± 0.27 3.0 ± 0.16 0.09 - 4.2 12 15 0.73 
E102Q K211M 8.7 ± 0.15 2.2 ± 0.06 0.28 - 18 6.9 15 1.7 
E102Q K211T 3.1 ± 0.06 2.6 ± 0.10 6.6 - 51 2.5 15 2.0 
T152K K211M 31 ± 0.39 2.0 ± 0.04 1.3 - 18 25 15 0.61 
T152K K211T 2.5 ± 0.05 2.1 ± 0.08 1.3 - 56 2.0 14 1.8 
T152V K211M 13 ± 0.19 2.3 ± 0.07 2.2 - 19 10 15 0.05 
E209Q K211M 27 ± 0.28 2.6 ± 0.06 3.2 - 16 21 14 1.1 
E209Q K211T 15 ± 0.37 2.7 ± 0.15 5.0 - 16 12 12 1.2 
K197M E209Q 36 ± 0.24 2.8 ± 0.04 4.6 - 12 29 11 0.65 
N101K K197M 24 ± 1.43 1.9 ± 0.18 0.05 - 0.74 19 12 0.43 
T152K K197M 32 ± 1.30 1.5 ± 0.08 0.08 - 1.8 25 10 0.35 
N101K T152K NR NR NR NR 9 NR 
N101K E209Q NR NR NR NR 16 NR 
E102Q T152V NR NR NR NR 10 NR 
E102Q T152K NR NR NR NR 5 NR 
E102Q E209Q NR NR NR NR 8 NR 
T152K E209D NR NR NR NR 15 NR 
T152K K211T E102Q NR NR NR NR 9 NR 
†kcal•mol-1; NR = no response; ± indicates SEM.     
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In an effort to further probe this ostensible role of positive charge, the single-
mutants N101K, E102Q, and E209Q, and the double mutants N101K/K211T, 
E102Q/K211T, and E209Q/ K211T were evaluated (Figure 2.9A, 2.9B, and 2.9C 
respectively; Table 2.6). We measured ∆∆G° = 0.73, 2.0, and 1.2 kcal•mol-1, respectively 
for these three double mutant pairs. Thus, all three pairs of mutations are meaningfully 
coupled, albeit to differing 
degrees. Recall the large 
coupling (∆∆G° = 1.8 
kcal/mol) for T152K/K211T, 
shown again in Figure 2.9D.  
We also generated the 
double mutants around the 
mutation K211M, the 
reasoning being that the 
nonpolar side chain of 
methionine is sterically 
similar to the lysine side 
chain, and does not introduce 
any other functionalities as in 
the case of the threonine 
hydroxyl in K211T. The 
∆∆G° values observed for the 
double mutants N101K 
 
Figure 2.8. Greatest-magnitude coupling energies 
observed between pairs of mutations at residues in 
5-HT3ARs. Meaningful coupling energies are depicted 
in color, with a different color for each additional 2-
fold deviation from additivity. Full data can be found 
in Tables 2.1 and 2.6. 
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K211M, E102Q K211M, T152K K211M, and E209Q K211M were 0.91, 1.7,  0.61, and 
1.1 kcal•mol-1, respectively (Figure 2.9; Table 2.6). We also generated the double mutant 
T152V K211M, for which the ∆∆G° value was only 0.05kcal•mol-1 (Table 2.6), 
demonstrating that a positive charge must be introduced at T152 in order to couple to K211.  
 
Figure 2.9. In 5-HT3ARs, mutations which remove the cationic amine on K211 
functionally couple to nearby mutations which introduce positive charge. A, 
Mutant cycles with N101K. B, Mutant cycles with E102Q. C, Mutant cycles with 
E209Q. D, Mutant cycles with T152K. Full pharmacological data can be found in 
Table 2.6. Error bars represent S.D. 
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Interestingly, each of the mutations that introduce a net positive charge couple 
comparably to K211T and K211M, with the exception of T152K. This mutation couples 
strongly to K211T (∆∆G° = 1.8 kcal/mol) but more weakly to K211M (∆∆G° = 0.61 
kcal/mol). That is to say, the K211T mutation rescues function of T152K more than eight 
times better than K211M does (Figure 2.9D). We therefore argue that there is a direct 
interaction between T152 and K211 in the 5-HT3AR, the likes of which cannot be accounted 
for by merely eliminating the nearby positive charge of the K211 side chain. On the other 
hand, the deleterious effects of introducing a net positive charge either by introducing 
N101K, E102Q, or E209Q, are attenuated whenever the basic amine on K211 is removed, 
regardless of the ability of the residue at position 211 to hydrogen bond.  
We also considered another charged residue, K197, that seemed a good candidate 
for coupling based on its proximity to the residues heretofore examined. In the GABAAR, 
a functionally important salt bridge has been demonstrated between residues aligning to 
K197 and T152.35 The 5-HT3AR mutation K197M couples weakly to the nearby E209Q 
(∆∆G° = 0.65 kcal•mol-1) and N101K (∆∆G° = 0.43 kcal/mol), but it does not couple 
meaningfully T152K (∆∆G° = 0.35 kcal•mol-1) (Table 2.6).  
Previously, we proposed a strategy for evaluating the role of a particular residue in 
channel function by evaluating its coupling to a residue in the pore-lining M2 helix that is 
clearly involved in channel gating.36 In the nAChR, that residue is termed Leu9’ (the 9th 
residue from the bottom of the M2 helix). In the nAChR, our group found that D200N 
couples strongly to L9’S (∆∆G = 1.3 kcal/mol), establishing a role in gating for D200.37 
However, K145Q and T202Tah (Tah = α-hydroxy threonine – a backbone mutation) do 
not show strong coupling to L9’S.37  
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In the 5-HT3AR, the appropriate mutation is T6’S (T257S in our numbering 
scheme), which has been used extensively to modulate serotonin receptor currents.38 We 
looked for coupling to T6’S at N101, E102, T152, and E209. The results are tabulated in 
Table 2.7 and presented pictorially in Figure 2.10. We find that N101K, E102Q, T152V, 
and T152K are all meaningfully coupled to T6’S, suggesting a role in gating for these 
residues.37 Interestingly, E209D and E209Q do not show meaningful coupling to T6’S. 
Thus, the nAChR and the 5-HT3AR show different coupling behaviors to the pore-forming 
M2 helix. In the muscle-type nAChR triad, the D200N mutation couples to L9’S but 
K145Q does not. The opposite coupling pattern is observed at the aligning sites in the 5-
HT3AR: T152K couples to T6’S while E209D does not. We are unable to perform the same 
analysis for the 5-HT3R mutation K211T, as none of the mutants we studied at this site 
lead to an interpretable loss of function relative to wild-type. However, we do note that 
mutations K211 couple energetically to all of the residues that couple to T6’S. 
Attempted expression of the 5-HT3AR double mutants E102Q/T152V, 
E102Q/E209Q, N101K/E209Q, and T152K/N101K yielded no measurable response to 
high concentrations of 5-HT (Table 2.6). This may result either from nonfunctional 
Table 2.7 
Mutant cycles between residues of interest in the 5-HT3AR and the channel pore 
mutation T6’S. Data for wild-type type and single mutants can be found in Table 2.6. 
 
†
kcal•mol
-1
; ± indicates SEM. 
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receptors or a lack of surface 
expression. Especially for the less-
conservative mutations we 
employ, individual mutations 
likely affect multiple interactions 
involved in receptor function, the 
deleterious effects of which may 
sometimes add together even if 
other pairs of mutations at the 
same sites generate functional 
receptors.  
2.4 Conclusions 
We have identified a triad of residues with one cationic, one anionic, and one 
hydroxyl-containing side chain that is rearranged between the 5-HT3AR, nAChRs, and 
GABAARs, and behaves differently in different receptors. In the muscle-type nAChR, the 
three triad residues cooperate as a unit, as demonstrated via triple mutant cycle analysis. 
This corroborates previous functional and crystallographic work that suggested a salt 
bridge between two members of the triad is involved in receptor gating.13,22,23,27 We show 
here that the salt bridge between K145 and D200 depends on T202, which may coordinate 
this interaction. Mutant cycles of the aligning residues in the 5-HT3AR indicate that T152, 
E209, and K211 cooperate in the activation mechanism of the 5-HT3AR, but not in a 
perfectly codependent manner. Interestingly, the triads of the 5-HT3AR and the nAChR can 
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Figure 2.10. Mutant cycles between residues of 
interest in the 5-HT3AR and the channel pore 
mutation T6’S. Receptor function is rescued upon 
inclusion of the T6’S mutation for all sites except 
E209. Full data, including that for other mutant 
pairs, is provided in Table 2.7. 
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be swapped and still produce functional receptors with small but meaningful losses of 
function.  
The triad of residues in the 5-HT3AR affects the competitive binding of nicotine for 
the orthosteric site. Each mutation on its own causes a decrease in nicotine binding affinity, 
although the shift for T152K is very small. Interestingly however, nicotine bound more 
strongly to 5-HT3AR variants with both the T152K and K211T mutations relative to wild-
type receptors. The E209D mutation, which causes a large loss of nicotine binding affinity 
on its own, increases the binding affinity for the triple mutant T152K/E209D/K211T 
relative to double mutant T152K/K211T. These three residues thus cooperate in the binding 
of nicotine to the 5-HT3AR, and likely represent a characteristic network of nAChRs. Worth 
noting is that two of the three deviations from the cationic/anion/hydroxyl triad of nAChRs 
are seen in the α9 and α10 nAChRs, which are inhibited rather than activated by nicotine.39 
In these nAChR α-subunits, the lysine residue of the triad is replaced by a threonine. It has 
been demonstrated elsewhere, however, that mutating the α9 Thr to a Lys does not produce 
receptors that are activated by nicotine,40 so clearly there is more to nicotine’s inhibitory 
effect on these receptors than this one residue.  
The triad from the GABAAR does not appear to function in the 5-HT3AR, 
suggesting this network functions differently in GABAARs. Other work has proposed a 
functionally important salt bridge between residues in the GABAAR aligning to K197 and 
T152 in the 5-HT3AR,
35 however we do not observe meaningful functional coupling 
between mutations at these sites in the 5-HT3AR. We also note that the pattern of 
functionalities in the triad we have studied is not conserved in primary-face α-subunits of 
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inhibitory GlyRs. All this together suggests that the triad of residues behaves similarly in 
excitatory receptors, but is functionally distinct in inhibitory Cys-loop receptors. 
Many amino acid residues we’ve considered in this study have been examined 
previously in regard to ligand binding. Based on radioligand binding studies of the 5-
HT3AR antagonist 
3H-granisetron, it has been proposed that T152 helps to shape the binding 
site.41 Mutations to 5-HT3AR residues E209 and K211 have been shown previously to have 
minimal effect on binding of 3H-granisetron.34,41 Our results show a minimal effect on 
nicotine binding for T152K, a modest effect for K211T, and a sizable effect for E209D. 
The effects of these mutations are observed to be cooperative, as single-mutants decrease 
the binding affinity of nicotine but have non-additive effects when the mutations are 
combined. Thus, these results highlight different binding modes for different competitive 
antagonists.  
We further investigated the involvement of residues in the gating mechanism via 
mutant cycle analyses to the channel gate mutation T6’S. Loop A residue N101 couples to 
T6’S, supporting a previous proposition that this residue is involved in receptor gating.34 
The mutation E102Q couples to T6’S, in line with a previously-published result.28 We 
observe that the T152K mutation affects ligand binding and also couples to the T6’S; thus 
we propose that this residue is involved in both binding and gating. We have not identified 
any single mutations to K211 that generate interpretable shifts in 5-HT EC50, so we were 
unable to perform the same analysis on this residue. However, spatially proximal residues 
that couple to the channel gate (N101, E102, and T152) also couple to K211. 
Quizzically, mutant cycles between E209 and T6’S do not reveal functional 
coupling between these residues, despite the previously published observation that E209 
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does not participate in the binding of 3H-granisetron.41 It is thus possible that E209 may 
contribute to the binding of 5-HT but not granisetron. In support of this explanation, recent 
cryo-EM structures of the 5-HT3AR in the presence of tropisetron (a close structural relative 
of granisetron) and 5-HT demonstrate much closer interatomic distances between the E209 
carbonyl and the 5-HT amine (4.3Å) versus the tropisetron amine (9.3Å; Figure 2.11).9  
While this is not conclusive evidence that E209 interacts directly with 5-HT, the 
experimental results reported herein together with structural work9 and computational 
predictions42 strongly suggest that E209 is involved in binding 5-HT.  
Mutations that introduce a net positive charge in the region of the 5-HT3AR probed 
here generally increase the 5-HT EC50 by a substantial amount. Most of these large losses 
of function could be rescued by mutations that remove the side-chain amine of K211. An 
exception is the highly deleterious T152K mutation, which can be rescued by the K211T 
mutation – corresponding to the nAChR swap – but not by the K211M mutation. This 
argues for a highly specific interaction between T152 and K211 in the native receptor.  
 
Figure 2.11. Comparison of binding poses for different ligands of the 5-HT3AR. 
(Left) Cryo-EM structure in which the amine of 5-HT may engage in a weak hydrogen 
bond with E209; PDB ID 6HIO. (Right) Cryo-EM structure demonstrating no 
hydrogen bond between E209 and the amine of tropisetron; PDB ID 6HIS.  
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We have demonstrated via mutant cycle analyses that triad residues and loop A 
residues are functionally coupled in the 5-HT3AR. Structural studies suggest similar 
interactions between the triad and loop A in nAChR. However, a previously established 
interaction between triad residues and loop C in nAChRs does not carry over to the 5-
HT3AR. These results highlight the fact that there is considerable variation in the degree to 
which structurally/functionally important features are or are not conserved across members 
of the Cys-loop family.  
2.5 Experimental Procedures 
2.5.1 Molecular biology 
The cDNA for the mouse 5-HT3R A subunit was in the pGEMhe vector. The cDNA 
for the mouse nAChR α1, ß1, γ, and δ were in the pAMV vector. The α1 subunit contains 
a hemagglutinin epitope tag in the M3-M4 loop, which does not alter the EC50 of ACh. 
Site-directed mutagenesis was performed using a QuikChange mutagenesis kit 
(Stratagene). cDNA was linearized using XhoI (New England Biolabs) for m5-HT3A, XbaI 
(New England Biolabs) for mα1, or NotI (New England Biolabs) for mß1, mγ, and mδ 
subunits. Linearized DNA was purified using a Qiaquick PCR Purification Kit (Qiagen) 
before performing an in vitro runoff transcription using a T7 mMessage mMachine kit 
(Ambion). The mRNA was purified using an RNEasy Mini Kit (Qiagen) and 
concentrations were quantified via UV-Vis spectroscopy (Nanodrop 2000, ThermoFisher 
Scientific). cDNA was stored at -20ºC and mRNA was stored at -80ºC.  
2.5.2 Protein expression in Xenopus laevis Oocytes 
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Stage V-VI Xenopus laevis oocytes were prepared as previously described.43 
Oocytes were injected with 50nL of mRNA in nuclease-free water, and expression levels 
of different mutants were optimized by varying mRNA concentrations and incubation 
times. For experiments involving 5-HT3AR variants, oocytes were injected with 5-50ng 
mRNA once at 24h before, once at 48h before, or twice at 24h and 48h before 
electrophysiological recording was performed. For experiments involving muscle-type 
nAChRs, oocytes were injected with a mixture of α1, ß1, γ, and δ mRNAs in a 10:5:5:5ng 
ratio (per 50nL) once at 24h before, once at 48h before, or twice at 24h and 48h before 
electrophysiological recording was performed. Cells were incubated at 18ºC in ND96 
(96mM NaCl, 2mM KCl, 1mM MgCl2, 1.8mM CaCl2, and 5mM HEPES at pH 7.5) with 
0.05mg/mL gentamycin (Sigma Aldrich), 2.5mM sodium pyruvate (Acros Organics), and 
0.67mM theophylline (Sigma Aldrich).  
2.5.3 Whole-cell electrophysiological recording 
Electrophysiology and drug perfusion were performed at ambient room 
temperature (20-25ºC) using the OpusXpress 6000A (Axon Instruments) in two-electrode 
voltage clamp (TEVC) mode. Oocytes were impaled with borosilicate glass pipettes filled 
with 3M KCl (R = 0.3 – 3.0MΩ) and clamped at a holding potential of -60mV. Data were 
sampled at 125Hz. The running buffer was Ca2+-free ND96 (96mM NaCl, 2mM KCl, 1mM 
MgCl2, and 5mM HEPES at pH 7.5). Solutions of serotonin hydrochloride (Sigma 
Aldrich), acetylcholine chloride (Sigma Aldrich), and (-)-nicotine tartrate (Sigma Aldrich) 
were prepared 0-24h before recording from stock solutions stored at -80ºC.  
For dose-response experiments, cells underwent a 30s wash in Ca2+-free ND96 
before 1mL of each concentration of drug (dissolved in Ca2+-free ND96) was applied for 
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15s. Cells were then washed for 116s using Ca2+-free ND96 before subsequent doses. For 
slow-activating variants, 1mL of drug solution was applied for 15s and cells were incubated 
in the drug solution for an additional 15s before washout. For slow-deactivating variants, 
washout times were increased to 176s in between doses. The different procedure for slow 
activating/deactivating variants did not meaningfully change the overall dose-response 
relationships recorded versus the standard 15s application / 116s wash procedure.  
For Schild analysis experiments, cells were continuously perfused with Ca2+-free 
ND96 containing (-)-nicotine, and 1mL solutions of 5-HT in Ca2+-free ND96 with the 
requisite concentration of (-)-nicotine were applied for 15s per dose, followed by 116s 
washes in between doses. As in the dose-response experiments, application times and wash 
times were adjusted for variants displaying slow activation/deactivation.  
2.5.4 Data analysis 
Raw TEVC traces were prepared and analyzed in Clampfit 10.3 (Axon 
Instruments). Raw data were first filtered using a lowpass Gaussian filter at 1Hz. A 30s 
baseline was established prior to each drug application during which cells were 
continuously perfused with Ca2+-free ND96. The averaged current of the baseline was 
subtracted from the peak amplitude following each drug application in order to generate 
dose-response data.  
Dose-response data for individual concentrations were averaged, plotted, and fit to 
the Hill equation I / Imax = 1 / (1 + (EC50 / [agonist]
nH) in Prism 7 (GraphPad), where EC50 
is the concentration for a half-maximal response, nH is the Hill coefficient, and I / Imax is 
the normalized response at a given drug concentration. For dose-response experiments, 
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data were normalized to the maximum current observed. Schild fits were determined and 
plots were made using Prism 7. The values for the slopes are reported in the text as slope 
fit ± standard error.  
Coupling energies for double-mutant cycles were calculated using the formula G 
= -R*T*ln((EC50wt*EC50AB) / (EC50A*EC50B)), where R is the gas constant, T is 
temperature, A and B denote individual mutations, and AB denotes double mutant 
receptors. The value used for T was 293.15K.  
The sequence alignment in Figure 2.1B was performed in Clustal Omega using 
sequences from Uniprot corresponding to the following accession numbers: P46098 
(human 5-HT3A), P02708 (human α1 nAChR), Q15822 (human α2 nAChR), P32297 
(human α3 nAChR), P43681 (human α4 nAChR), P30532 (human α5 nAChR), Q15825 
(human α6 nAChR), P36544, (human α7 nAChR), Q9UGM1 (human α9 nAChR), 
Q9GZZ6 (human α10 nAChR), P18505 (human ß1 GABAA), P47870 (human ß2 GABAA), 
P28472 (human ß3 GABAA).
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Chapter 3: Probing proline residues in the prokaryotic ligand-gated ion channel, 
ELIC*†
 
3.1 Abstract 
Erwinia ligand-gated ion channel (ELIC) is a bacterial homologue of vertebrate 
pentameric ligand-gated ion channels (pLGIC), and has proved a valuable model for 
understanding the structure and function of this important protein family. There is 
nevertheless still a question as to whether molecular details can be accurately 
extrapolated from this protein to those found in eukaryotes. Here we explore the role of 
proline residues (Pros) in ELIC by creating mutant receptors, expressing them in 
Xenopus laevis oocytes, and using whole-cell voltage-clamp electrophysiology to 
monitor channel activity. In contrast to eukaryotic pLGICs, proline-to-alanine (Pro-to-
Ala) substitution in ELIC mostly resulted in gain of function, and even altering highly 
conserved Pro residues in M1 and the M2-M3 loop did not ablate function. These 
substitutions also mostly resulted in ablation of the modulation by Ca2+ observed in 
wild-type receptors.   Substitution of the Pro in the “Cys-loop”, however, did result in 
non-functional receptors. Probing this residue with non-canonical amino acids revealed 
a requirement for a substituted amine at this position, as well as a general preference 
for Pro analogues with greater intrinsic cis biases. We propose there is likely a cis bond 
at the apex of the Cys-loop in this protein, which is consistent with some, but not all, 
findings from other pLGIC. Overall, the data show that the roles of proline residues are 
less critical in ELIC than in other pLGIC, supporting other studies that suggest caution 
                                                     
* This chapter is adapted with permission from: Mosesso, R., Dougherty, D. A. & 
Lummis, S. C. R. Probing Proline Residues in the Prokaryotic Ligand-Gated Ion 
Channel, ELIC. Biochemistry 57, 4036–4043 (2018). 
† A substantial amount of the experimental work in this chapter was performed by 
Prof. Sarah C.R. Lummis. These sections are denoted with asterisks.  
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must be applied in using data from this prokaryotic receptor to understand molecular 
details of eukaryotic pLGIC receptor function.  
3.2 Introduction 
The Cys-loop family of pentameric ligand-gated ion channels (pLGIC) is 
comprised of proteins responsible for fast excitatory and inhibitory synaptic 
neurotransmission in the central and peripheral nervous systems. Members of this 
family, which includes nicotinic acetylcholine (nACh), 5-HT3, GABAA, and glycine 
receptors, share a pentameric structure, with each of the subunits having extracellular, 
transmembrane, and intracellular domains. Neurotransmitters bind at the interface 
between two adjacent subunits in the extracellular domain (ECD), triggering a 
conformational change that opens the pore, which consists of five helices, one (M2) 
from each subunit.1–3. 
The mechanism of transduction of binding information to the pore remains as a 
significant challenge. Recent publication of high-resolution structures of the first 
mammalian Cys-loop receptors (nACh, GABAA, 5-HT3, and glycine)
4–8 has been 
enlightening, but information is still sparse compared to many other ion channels. Thus, 
many researchers are using prokaryotic pLGICs from Erwinia chrysanthemi (ELIC) 
and Gloeobacter violaceus (Gloeobacter ligand-gated ion channel; GLIC), as model 
systems.9–13 These prokaryotic receptors share the general structure of the Cys-loop 
receptors, but lack the large, variable intracellular domain. In addition, the cysteines in 
the eponymous Cys-loop are absent in ELIC and GLIC, but the loop structure remains. 
GLIC has proved especially popular, with well over 70 structures in the RCSB Protein 
Data Bank. Nevertheless, the mechanism of ELIC is probably more similar to Cys-loop 
receptors, as it is activated by binding of small amines such as GABA at the orthosteric 
binding site,10,14 whereas GLIC is activated by protons.11,15,16 
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We do not yet know, 
however, how closely ELIC 
models its eukaryotic relatives, and 
a recent report states that ELIC has 
atypical gating and conductance 
properties compared to other 
pLGIC.17 In an effort to identify 
critical differences/similarities 
between ELIC and the eukaryotic 
Cys-loop receptors, we have 
chosen to focus on the proline 
residues of ELIC. Pro differs from 
other naturally occurring amino 
acids by its limited hydrogen 
bonding capability, increased steric 
bulk at the backbone nitrogen, and 
greater propensity to exist in a cis 
conformation at the peptide 
bond.18,19 As such, proline residues 
often play critical functional roles 
and are frequently highly 
conserved in membrane receptors. Which of the unique Pro features is essential for 
function has previously been determined at specific locations in GLIC and some 
eukaryotic Cys-loop receptors.20–22 ELIC has 15 Pro residues in each subunit (Figure 
3.1); some of these are at locations conserved in other pLGIC, while others are not  
 
Figure 3.1. Location of Pro residues in a 
single ELIC subunit (PDB ID 3RQU). (A) 
Top-down view of ELIC, showing five 
subunits around the pore. (B) Single subunit 
of ELIC with Pro residue side-chains shown 
as blue spheres. 
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Figure 3.2. Clustal alignment of ELIC and other pLGIC subunits showing 
the location of the Pro residues examined in this study (red), approximate 
locations of the binding loops (red bars) and transmembrane -helices 
(black bars), and conservation of amino acid side chain chemistry (gray 
boxes). 
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(Figure 3.2).  Here we explore the roles of these residues using natural and non-
canonical amino acid mutagenesis of Pro residues in ELIC, expressed in Xenopus laevis 
oocytes and characterized using two-electrode voltage clamp electrophysiology.     
3.3 Results and Discussion 
3.3.1 Many Pro-to-Ala substitutions change functional parameters*  
To probe the nature of the 15 Pro residues in each ELIC subunit, we mutated 
each to Ala and determined changes in functional characteristics following expression 
in Xenopus oocytes. Mutation of 14 of these to Ala resulted in functional receptors, 
indicating only one (P120) is critical for ELIC function.  
Concentration response curves revealed EC50s in the functioning mutant 
receptors varied between 4.4 and 92 mM, and all except one (P210A, the conserved Pro 
 
NF = non-functional; pEC50 data = mean ± SEM. *, **, ***, **** = significantly 
different (p <0.05, 0.01, 0.001, 0.0001, respectively). 
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in the M1 helix) were significantly different to wild type ELIC (EC50 36 mM) (Table 
3.1).  Most of the changes were to a lower EC50, indicating GABA was more potent at 
these altered receptors, although one (P182A, a non-conserved Pro located in binding 
loop C) resulted in an increased EC50. 
These experiments were performed in Ca2+-containing buffer. Modulation by 
divalent cations, and particularly Ca2+, is common in pLGIC, but the effect is especially 
pronounced in ELIC, where it has been extensively investigated.23,24 To probe if there 
were Ca2+-related effects in our mutant receptors,  the Ala mutagenesis experiments 
were repeated on all mutants in Ca2+-free buffer. The presence or absence of Ca2+ 
significantly affects the functional characteristics of wild-type ELIC (as previously 
reported)23 causing changes in the shape of the responses (Figure 3.3A) and also the 
EC50 and Hill coefficient (nH): the EC50 decreased from 36 mM to 6.6 mM  and nH 
increased from 1.7 to 3.3 (Tables 3.1 and 3.2).   
 
Figure 3.3. Effects of Ca2+ on ELIC and ELIC Pro mutants. (A) Effects of Ca2+ 
on typical maximal responses of wild-type and exemplar mutant ELIC to GABA. 
Scale bars = 5 A and 10s.  (B) Comparing effects of Ala substitutions of Pros in 
ELIC on GABA pEC50 values in Ca
2+-containing buffer versus Ca2+-free buffer. Data 
from which these values were derived are shown in Tables  1 and 2. ★ = significantly 
different to WT, p < 0.05. (Experiments performed by Prof. Sarah Lummis.) 
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The use of Ca2+-free buffer had a quite different effect on the mutant receptors. 
We observed similar effects on the shapes of the responses (Figure 3.3A), but, while 
13 of the 14 functional Pro-to-Ala variants had pEC50 values that were statistically 
different from wild-type ELIC in buffer containing Ca2+, only two variants (P253A and 
P256A) had statistically significant changes in pEC50 in Ca
2+-free buffer (Figure 3.3B, 
Table 3.1).  Also in contrast to wild-type ELIC, 10 of the 14 functional mutants (all but 
P74A, P182A, P253A, and P256A) did not have statistically significant differences in 
pEC50 between Ca
2+-containing buffer and Ca2+-free buffer (rightmost column, Table 
3.1). Thus Ca2+ sensitivity is ablated in most of the Pro-to-Ala mutants, and the response 
to GABA of Pro-to-Ala mutants is generally more similar to wild-type ELIC in the 
absence of Ca2+. 
Table 3.2  
Hill coefficients of Pro-to-Ala ELIC mutants in the presence and absence of Ca
2+
. 
(Experiments performed by Prof. Sarah Lummis.) 
 
NF = non-functional; n
H
 data = mean ± SEM. *, **, ***, **** = significantly 
different (p <.05, .01, .001, .0001, respectively) 
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A similar pattern is observed when analyzing changes in nH (Table 3.2). Four 
of the fourteen functional Pro-to-Ala mutants display statistically-meaningful changes 
in nH relative to wild-type ELIC in Ca
2+-containing buffer. However, none of the 
functional mutants has a nH that is statistically different from wild-type in Ca
2+-free 
buffer. This amounts to statistically-meaningful differences in nH in the presence versus 
the absence of Ca2+ for wild-type ELIC which are ablated in all mutants except P51A, 
P74A, P182A, and P253A (see rightmost column, Table 3.2).  
Such dramatic effects of Ca2+ have not typically been observed for other 
pLGICs, although modulatory effects of Ca2+ that can enhance or inhibit responses are 
common.23,25–30 The binding sites of Ca2+, identified using structural and functional 
experiments, have been shown to be between subunits (Figure 3.4), and Ca2+ binding 
impacts gating.29 Given the apparent loss of a modulatory effect in most of the Pro-to-
Ala mutants, it is interesting to consider if there is a relationship between Ca2+ 
modulation and the role of Pros in gating.  Overall, Pro-to-Ala mutations increased 
sensitivity of mutant receptors to GABA in the presence of Ca2+ while the same 
mutations cause no change in the absence of Ca2+ – ten of the fifteen Pro-to-Ala mutants 
fit this pattern. Intriguingly, the only mutants that do not are P120A (ß6-ß7 loop), 
P182A (loop C), P210A (conserved M1 Pro), P253A (M2-M3 loop), and P256A (M2-
M3 loop), all of which are located in regions of the protein that have been previously 
identified in ELIC and other pLGICs as playing important roles in receptor gating.1,3,31  
We suggest that the Pros in ELIC that are not located in the transduction pathway help 
to organize the structure in such a way that it can be modulated by Ca2+. 
The only statistically meaningful loss of function (other than the nonfunctional 
P120A) we observed for a Pro-to-Ala mutation in ELIC was P182A. This Pro is located 
in loop C, which has been identified in numerous studies of pLGICs to play a key role 
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in agonist binding and channel gating.32,33 These data therefore confirm the importance 
of loop C in ELIC function.  
3.3.2 Non-canonical amino acid mutagenesis of Pro120 
 
Figure 3.4. Divalent cation binding-site in ELIC, as exemplified by a crystal 
structure with Ba2+ (PDB 2YN6). Two subunits of the homopentamer are 
shown. The primary face is shown in light gray with Pro side chains in blue, 
while the complementary face is shown in black with Pros in yellow. Oxygen 
atoms on negatively-charged residues in the divalent cation binding site are 
shown in red, and the Ba2+ ion is shown in green. The site illustrated in this figure 
was shown to be responsible for the modulatory effect of Ca2+.26 
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The ß6-ß7 loop in ELIC does not contain a disulfide bond as in eukaryotic 
pLGICs, but the equivalent region is homologous in many regards.31,34 Most 
particularly it has a central Pro residue bounded by two aromatic residues. Substitution 
of this Pro with naturally occurring amino acids in all Cys-loop receptors tested to date 
results in non-functional receptors,20,22,35 and our data in ELIC are similar. Since 
conventional mutagenesis of these Pros is disruptive to function, we have implemented 
the subtler probe of non-canonical amino acid mutagenesis. This method enables us to 
incorporate Pro analogues and other non-canonical amino acids of varying ring size, 
side chain substitution, and intrinsic preferences for the cis conformer (Figure 3.5A). 
A wild-type rescue experiment (i.e. incorporating Pro using in vivo non-canonical 
amino acid mutagenesis) revealed similar characteristics to wild-type ELIC, indicating 
that the non-canonical amino acid mutagenesis methodology is working appropriately. 
Many of the non-canonical amino acids yielded functional receptors (azetidine-2-
carboxylic acid (Aze), pipecolic acid (Pip), morpholine-3-carboxylic acid (Mor), cis-4-
fluoroproline (cis-F-Pro), trans-4-fluoroproline (trans-F-Pro), and N-methylalanine 
(N-Me-Ala), and all of these had EC50 and nH values similar to wild-type (Figure 3.5B; 
Table 3.3). However, attempted incorporation of 3-methylproline (3-Me-Pro), 2-
methylproline (2-Me-Pro), N-methylleucine (N-Me-Leu), and lactic acid (Aah, or -
hydroxyalanine) resulted in no measurable response.  
The particular properties of Pro have resulted in its playing highly specific roles 
in transmembrane proteins, and we have identified 3 distinct Pro characteristics: (1) 
lack of a backbone hydrogen bond, (2) cis-bias of the prolyl peptide bond, and (3) 
substitution of the amine. For a given Pro, any of these could be a key characteristic 
required at a specific location in a pLGIC for wild type function.  
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To test the requirement for lack of a hydrogen bond, we introduced Aah, which 
generates receptors with a backbone ester in place of an amide at the site of 
 
Figure 3.5. Non-canonical amino acid mutagenesis of ELIC P120. (A) 
Structures of non-canonical amino acids used in this study. Amino acids in the 
solid box were successfully incorporated whereas those in the dashed box either 
did not incorporate or generated non-functional receptors. (B) Dose-response 
curves comparing responses of ELIC to GABA for incorporation of Pro versus 
non-canonical amino acids. Parameters derived from these curves are shown in 
Table 3.3. 
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incorporation. At other Pros – for example the highly conserved Pro in the middle of 
M1 (P210 in ELIC) – this change leads to functional channels with near wild type 
behavior. However, this analog resulted in no functional response at the 120 site, 
suggesting that the most salient aspect of Pro at this position is not its inability to act as 
a hydrogen bond donor. This is also an outcome that would be expected if cis–bias was 
a factor (option 2), since this substitution would disfavor a cis peptide bond.  
Support for option 2 comes from our data showing functional responses upon 
incorporation of analogs with increased cis-bias relative to Pro, i.e. Aze, Pip, Mor, and 
cis-F-Pro. The %cis of these residues when adjacent to a phenylalanine is 30%, 39%, 
48%, and 32%, respectively, compared to 17% for Pro.22 Incorporation of two Pro 
analogues with a lower %cis, 3-Me-Pro (12%) and 2-Me-Pro (0%), resulted in non-
functional receptors, consistent with a requirement for a cis peptide bond at this position. 
An inconsistency is seen, however, with trans-F-Pro. Despite having a lower intrinsic 
Table 3.3 
Functional parameters for non-canonical amino acid incorporation at P120 in 
ELIC
a
  
 
aNF= non-functional; ND = not determined. pEC50 data = mean ± SEM. No 
values were statistically different to WT. %cis values for Pro, Pip, Aze, cis-F-Pro, 
3-Me-Pro, 2-Me-Pro, and Mor were determined from NMR analysis of GFXG 
tetrapeptides22 while that for trans-F-Pro was determined using a different 
approach.18 
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cis preference than Pro (12% versus 17%),18 trans-F-Pro yields no meaningful 
functional differences from wild-type ELIC when incorporated in place of P120. It is 
perhaps salient that this %cis value was not determined from trans-F-Pro with an 
adjacent aromatic residue, which affects cis/trans ratios of Pro amide bonds, and thus 
the value of 12% may be an underestimate in this situation.36,37 Still, trans-F-Pro has a 
higher intrinsic cis bias than any naturally-occurring amino acid other than Pro.  
The N-substituted amino acids N-Me-Ala and N-Me-Leu were incorporated in 
place of P120 in order to probe option 3, amine substitution. N-Me-Ala incorporation 
yielded functional receptors with pharmacological properties very similar to wild-type 
ELIC. Note that an N-substituted peptide bond is also expected to exist more in the cis 
conformation than a conventional amino acid.38,39 However, incorporation of N-Me-
Leu in place of P120 yielded no measurable response. This, together with the 
observation that 3-Me-Pro also failed to generate functional receptors, can perhaps be 
rationalized by considering branching of the side chain. N-Me-Leu and 3-Me-Pro failed 
 
Figure 3.6. Analysis of the conformations about the completely-conserved ß6-
ß7 loop prolyl peptide bond in pLGIC structures. (A) Correlation between 
higher structural resolution and assignment of a cis peptide bond. 142 X-ray 
crystal structures and cryo-EM structures of full-length pLGICs were included in 
this analysis. (B) Correlation between higher structural resolution and assignment 
of a cis peptide bond is still present when considering only full-length mammalian 
pLGIC structures.  
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to give functional receptors, and these are also the only two amino acids studied herein 
with tertiary carbon centers on their side chains. This sensitivity to side chain branching 
at P120 in ELIC would distinguish it from other pLGICs, where functional 
incorporation of 3-Me-Pro at the equivalent position has been seen.20,22 
Together, the data using non-canonical amino acid mutagenesis of P120 suggest 
a requirement for substitution of the amine, as well as a preference for a cis peptide 
bond at this position. Further support for the presence of a cis peptide bond comes from 
an analysis of pLGIC structures in the RCSB Protein Data Bank. Of the 142 pLGIC 
structures we examined, 101 were found to have the ß6-ß7 loop Pro in the cis 
conformation. Moreover, we observe a statistically significant correlation between the 
resolution of the structure and the presence of a cis peptide bond at this Pro; higher-
resolution structures tend to assign the cis conformation while those of lower resolution 
tend to assign a trans peptide bond (p < 0.0001, Figure 3.6A). While there are still 41 
pLGIC structures with trans peptide bonds to this Pro, it seems that the peptide bond is 
more likely to be simply assigned a trans conformation when the resolution is too low 
to observe the peptide bond conformation definitively. The correlation is still present 
when the analysis is limited to structures of mammalian Cys-loop receptors (p = 0.0008, 
Figure 3.6B).  
3.4 Conclusions 
In conclusion, our data show that ELIC is largely tolerant of Pro-to-Ala 
substitutions, although we note key differences between functional changes in media 
with Ca2+ versus media without Ca2+; this tolerance differs from previously-observed 
results in other pLGICs, perhaps indicating a departure from a canonical mechanism of 
action of these proteins.  
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The absolutely-conserved P120 in the ß6-ß7 loop, however, is critical for 
receptor function. Investigations using non-canonical amino acids demonstrate that 
substitution of the amide nitrogen is key at this position, and also highlight a potential 
role for a cis peptide bond. Comparisons with other pLGICs show that the role of this 
Pro in ELIC may contribute in a similar manner to that in other pLGIC. 
3.5 Experimental Procedures 
3.5.1 Molecular biology 
The cDNA for ELIC was in the pGEMhe plasmid. Site-directed mutagenesis 
was performed using the Stratagene QuikChange protocol to generate the appropriate 
codon. For non-canonical amino acid mutants and conventional mutants generated by 
non-canonical amino acid mutagenesis, the site of interest was mutated to the TAG stop 
codon. Plasmids were linearized with the SbfI restriction enzyme, and receptor mRNA 
was then prepared by in vitro runoff transcription using the Ambion T7 mMessage 
mMachine kit. 
  Hydroxy or 4,5-dimethoxy-2-nitrobenzyloxycarbonyl (NVOC) 
protected amino acid-dCA couples were enzymatically ligated to truncated 74mer 
THG73 tRNA as previously described.40,41 The 74mer tRNA was prepared using the 
Ambion T7MEGAshortscript kit by transcription from a modified DNA 
oligonucleotide template as described in the literature to enhance RNA transcript 
homogeneity.42 Crude tRNA-amino acid or tRNA-hydroxy acid product was used 
without desalting, and the product was confirmed by matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry on a 3-hydroxypicolinic acid matrix. 
Deprotection of the NVOC group on the tRNA-amino acids was carried out by 5-min 
photolysis on a 1 kW xenon lamp with WG-335 and UG-11 filters or for 2.5-min using 
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a 1150mW 365nm LED (Thorlabs) immediately prior to injection. Either deprotection 
strategy yielded fully deprotected aminoacyl tRNAs as assayed by MALDI-TOF mass 
spectrometry.  
3.5.2 Oocyte preparation and RNA injection 
Stage V-VI oocytes of Xenopus laevis were harvested and injected with RNAs 
as described previously.41 For non-canonical amino acid mutagenesis experiments, 
each cell was injected with 50-100 ng each of receptor mRNA and appropriate tRNA 
approximately 48h before recording. Mutants yielding small responses required 72h of 
incubation, with a second injection of mRNA and tRNA 48h before recording.  
 For wild type experiments and conventional mutants, each cell received 
a single injection of 1-25 ng of receptor mRNA approximately 24 h before recording. 
Injection volumes for each injection session were 50-100 nL per cell.  
 As a negative control for suppression experiments at each site, 
unacylated full-length tRNA was co-injected with mRNA in the same manner as 
charged tRNA. These experiments yielded negligible responses for all sites. Wild-type 
recovery conditions (injecting tRNA charged with the appropriate amino acid to 
regenerate a wild type channel via non-canonical amino acid mutagenesis at a TAG 
stop codon) were injected alongside mutant non-canonical amino acid mutagenesis 
conditions as a positive control.  
3.5.3 Electrophysiology 
Oocyte recordings were made in two-electrode voltage clamp mode using the 
OpusXpress 6000A (Axon Instruments). Oocyte equilibration and washes were 
performed with ND96 (96 mM NaCl, 2 mM KCl, 1.8m CaCl2, 1 mM MgCl2, 5 mM 
HEPES, pH 7.4). Initial holding potential was -60 mV. Data were sampled at 125 Hz 
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and filtered at 50 Hz. Micro-electrodes were fabricated from borosilicate glass 
(GC120TF-10, Harvard Apparatus, Kent, UK) using a one stage horizontal pull (P-87, 
Sutter Instrument Company, Novato, CA) and filled with 3M KCl. Pipette resistances 
ranged from 0.3 – 3.0 M. Analysis and curve fitting was performed using the 4 
parameter equation in Prism (GraphPad Software, La Jolla, CA). Concentration-
response data for each oocyte was normalized to the maximum current for that oocyte. 
Parameters were compared using ANOVA with a Dunnetts multiple comparisons test.  
Values of p < 0.05 were taken as significant. 
3.5.4 Analysis of ß6-ß7 loop proline peptide bond conformation 
 Only X-ray crystal structures and cryo-EM structures of full-length receptors 
were considered for analysis. The PDB IDs of the structures used for this analysis are 
as follows: Mammalian Cys-loop receptors: 5-HT3Rs: 4PIR, 6HIS, 6HIN, 6HIQ, 
6HIO, 6DG7, 6DG8. nAChRs: 2BG9, 6CNJ, 6CNK, 5KXI. GlyR α-subunit 
homopentamers: 5CFB, 3JAF, 3JAE, 3JAD, 5VDH, 5TIO, 5TIN, 5VDI. GABAAR ß3 
homopentamer: 4COF. GABAAR ß3-α5 chimeras: 5O8F, 5OJM. GABAAR 
heteropentamers: 6HUG, 6HUJ, 6HUK, 6HUO, 6HUP, 6DW0. Protostome Cys-loop 
receptors: GluCl: 4TNW, 4TNV, 3RHW, 3RIF, 3RI5, 3RIA. Prokaryotic pLGICs: 
GLIC & GLIC variants: 4HFI, 4IL4, 4HFH, 4HFE, 3EAM, 5HCJ, 4F8H, 4ILC, 4QH5, 
4HFD, 4ZZC, 5HCM, 3P4W, 4QH4, 5J0Z, 3P50, 5L47, 5L4H, 4QH1, 4ZZB, 4ILA, 
5L4E, 4NPQ, 3EHZ, 2XQ7, 2XQ3, 2XQ5, 2XQ4, 2XQ8, 2XQ6, 2XQA, 5MUO, 6F7A, 
3TLW, 3TLU, 3TLV, 3UU5, 3UUB, 3UU6, 3UU4, 3UU3, 3UU8, 4IL9, 4ILB, 5V6N, 
6F11, 6F0Z, 6F10, 6F12, 3TLS, 2XQ9, 3EI0, 6F0I, 6F0J, 6F0U, 6F0M, 6F13, 6F0N, 
6F0R, 6F0V, 4HFB, 4HFC, 5MUR, 5MVM, 5V6O, 3TLT, 6F15, 5MZR, 5MZT, 6F16, 
4LML, 5MZQ, 5MVN, 5HEG, 5HEH, 4LMJ, 5IUX, 4IRE, 4LMK, 5OSA, 5OSC, 
5OSB, 4NPP. ELIC & ELIC variants: 4Z90, 5SXU, 4TWD, 4A97, 4Z91, 5SXV, 4A98, 
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3ZKR, 2YOE, 4TWF, 3RQW, 3RQU, 2VL0, 2YN6, 5LG3, 5LID, 5HEJ, 4TWH, 
2YKS, 3UQ7, 3UQ5, 5HEO, 5HEW. ELIC/GLIC chimera: 4YEU. 
Mammalian/Prokaryotic chimera: GlyR/GLIC chimera: 4X5T. 
 Each structure was manually examined in Pymol 2.3 in regard to the 
conformation about the peptide bond to the conserved ß6-ß7 loop proline. Two 
structures (PDB ID 3RQW and 3UQ4) had an ambiguous, bent conformation about the 
prolyl peptide bond, and were excluded from this analysis. GraphPad Prism 7 was used 
to plot the data and analysis of statistical significance was performed using a 
nonparametric Mann-Whitney test.  
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Chapter 4: Molecular Details of 5-HT3AR Gating  
4.1 Abstract 
 Cys-loop receptors are ligand-gated ion channels that facilitate communication 
between cells of the nervous system and are implicated in a wide range of afflictions. Much 
is known about the binding of endogenous agonists and other ligands, however the process 
of allosteric communication of the ligand binding event into receptor activation, a process 
known generally as “gating,” is not as well-characterized. Herein we have used a 
combination of canonical and non-canonical amino acid mutagenesis and mutant cycle 
analysis in order to elucidate details of the gating mechanism of one Cys-loop receptor, the 
type 3 serotonin receptor (5-HT3R). The results reported in this study contribute to our 
understanding of 5-HT3R and may provide valuable insights into the gating mechanisms 
of Cys-loop receptors as a whole. 
4.2 Introduction 
Communication between cells of the nervous system happens in part by the process 
of synaptic transmission, wherein neurotransmitters are released from a presynaptic cell to 
convey a signal to a postsynaptic cell.1–3 The sensing of neurotransmitters by the 
postsynaptic cell is achieved by the action of receptors on its surface, including pentameric 
ligand-gated ion channels (pLGICs) that convert a chemical signal in the form of ligand 
binding into an electrochemical signal in the form of ion flux across the membrane.1–3 
Many pLGICs have been studied extensively to date, but a significant amount of 
research has been done on vertebrate pLGICs, the so-called Cys-loop receptor superfamily, 
comprised of nicotinic acetylcholine receptors (nAChRs), type A γ-aminobutyric acid 
receptors (GABAARs), glycine receptors (GlyRs), and type 3 serotonin receptors (5-
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HT3Rs).
4–7 Within the Cys-loop receptor superfamily, 5-HT3Rs have garnered much 
interest.7–10 These receptors carry out fast excitatory neurotransmission by responding to 
their native agonist serotonin, also known as 5-hydroxytryptamine or 5-HT. 5-HT3Rs are 
abundant in the gastrointestinal tract, where they regulate physiological functions such as 
gut motility, peristalsis, and emesis.7,9 Currently-marketed pharmaceuticals targeting 5-
HT3Rs competitively antagonize the serotonin binding site, and are prescribed for the 
treatment of radiotherapy- or chemotherapy-induced nausea and vomiting, post-operative 
emesis, and irritable bowel syndrome.9,10 Additionally, 5-HT3Rs have been implicated in a 
range of other treatment areas including cognition, emotion, learning, anxiety, and bipolar 
disorder.10  
A single 5-HT3R is composed of five identical or homologous subunits assembled 
about a five-fold axis to form a central pore.7,8 In humans there are five distinct subunits of 
5-HT3Rs, assigned letters A through E. The A subunit can form homopentameric receptors, 
and is obligate for the formation of heteromeric receptors.7,8 Given that all 5-HT3Rs must 
contain the A subunit, all drugs on the market which target 5-HT3Rs have been 
characterized based on their action at homomeric 5-HT3ARs.
7 We too have focused our 
research on the homopentameric 5-HT3AR.  
In 5-HT3ARs, as with other Cys-loop receptors, the N-terminal domain folds into 
ten β strands, which assemble into a β sandwich to form the extracellular domain (ECD; 
Figure 4.1).1–3 The transmembrane domain (TMD) is comprised of four α-helices, 
numbered M1-M4; loops connecting the transmembrane helices extend into the 
intracellular and extracellular space.1–3 During receptor activation, the ligand binds at the 
interface between two subunits in the ECD, causing conformational changes collectively 
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known as “gating” that ultimately result in an expansion of the channel pore formed by the 
M2 helices, allowing the selective passage of ions across the cell membrane.1–3 
While structural studies of pLGICS have provided great insight into the global 
structural changes underlying activation of the 5-HT3AR and other pLGICs, the exact 
molecular details of the gating processes for different receptors have remained elusive.1,2,11 
Nonetheless, numerous studies across the pLGIC superfamily have highlighted the 
importance of a region at the interface between the ECD and TMD in channel gating.1,2,11 
Key secondary structures in this “interfacial region” include the ß1-ß2 loop, the Cys-loop 
(or ß6-ß7 loop in prokaryotic receptors, which lack the signature disulfide bond of 
eukaryotic receptors), the ß8-ß9 loop, the pre-M1 region, and the M2-M3 loop (Figure 
4.1).1,2,11 Herein we have performed mutagenesis experiments on the 5-HT3AR to define 
key chemical features of and functionally-relevant interactions between residues in the 
 
Figure 4.1. Overall topology of a single 5-HT3AR subunit (left) and interfacial 
region (right). Key structural elements of the interfacial region are highlighted and side 
chains of amino acid residues under investigation are shown as sticks. Red, ß1-ß2 loop; 
orange, Cys-loop; yellow, ß8-ß9 loop; green, pre-M1 region; blue, M2-M3 loop. For 
simplicity, carbon atoms and heteroatoms are the same color. PDB ID 6HIS.25 
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interfacial region of this receptor. In doing so, we aim to reconcile previous results 
regarding the roles of these residues and nearby residues in gating of the 5-HT3AR and 
other pLGICs. 
4.3 Results and Discussion 
4.3.1 Non-canonical amino acid mutagenesis of the 5-HT3AR Cys-loop proline
* 
In the namesake Cys-loop (the ß6-ß7 loop of prokaryotic pLGICs) of Cys-loop 
receptors, there is an absolutely-conserved proline that was shown to be critical for surface 
expression of 5-HT3ARs in a very early study.
12 Since then, the precise chemical features 
of the aligning proline have been examined in GLIC, ELIC, and the muscle-type nAChR 
by means of non-canonical amino acid mutagenesis.13–15 Herein we sought to perform the 
same type of analysis of the Cys-loop proline in the 5-HT3AR in order to compare results 
with those of other pLGICs.  
In all pLGICs, this proline is adjacent to at least one if not two aromatic amino acids 
(either phenylalanine or tyrosine).13–16 In addition to there being an increased prevalence 
of cis peptide bonds to proline residues relative to all other amino acids,17 it is well-
established that the presence of an aromatic residue immediately preceding a proline 
residue in the primary sequence increases the intrinsic cis bias of the prolyl peptide bond 
via polar-π interactions between the π system of the aromatic ring and hydrogens on the 
proline pyrrolidinyl ring.18–20  
We therefore sought to elucidate the salient chemical features of the Cys-loop 
proline residue in the 5-HT3AR, especially in regard to the conformation about the P143 
peptide bond. Employing both natural and non-canonical amino acids, we substituted P143 
                                                          
*Part of this section was written in collaboration with Prof. Sarah C.R. Lummis. 
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with an array of amino acids and amino acid analogs and characterized receptor function 
in response to 5-HT. The results are summarized in Table 4.1. Consistent with previous 
results, there was no measurable response up to 800µM 5-HT of 5-HT3ARs bearing Ala or 
Val substitutions for this proline. This could be due either to a lack of surface expression 
(presumably resulting from misfolding) or surface expression of nonfunctional receptors. 
We did not assay for surface expression, so either possibility is open. 
Given the results from the two natural mutants, we next attempted incorporation of 
non-canonical amino acid analogues at the proline site of interest. All told, we attempted 
incorporation of azetidine-2-carboxylic acid (Aze), pipecolic acid (Pip), morpholine-3-
carboxylic acid (Mor), cis-4-fluoroproline (cis-F-Pro), trans-4-fluoroproline (trans-F-Pro), 
Table 4.1 
Mutations to the 5-HT3AR Cys-loop proline, P143. 
Mutation %cisa EC50 (µM) nH |Imax|(µA) Fold N 
- 17 1.3 ± 0.03 2.4 ± 0.11 1.0 - 78 1.0 21 
Pro* 17 1.3 ± 0.03 2.7 ± 0.19 0.04 - 3.6 1.0 20 
3-Me-Pro 12 0.27 ± 0.01 2.6 ± 0.18 0.09 - 1.5 0.21 19 
Pip 39 0.53 ± 0.01  4.2 ± 0.34 0.37 - 6.2 0.41 23 
cis-F-Pro ND 0.58 ± 0.03 5.2 ± 1.3 1.1 - 8.8 0.45 8 
Aze 30 1.2 ± 0.14 1.1 ± 0.11 0.05 - 0.69 1.0 15 
trans-F-Pro 32 1.5 ± 0.05 2.1 ± 0.13 0.12 - 4.9 1.1 19 
N-Me-Ala ND 2.3 ± 0.10 2.4 ± 0.25 0.10 - 1.5  1.7 23 
dhP ND 4.0 ± 0.14 2.6 ± 0.19 0.50 - 1.5 3.1 10 
Mor 48 5.5 ± 0.14 2.1 ± 0.08 0.24 - 6.1 4.3 32 
2-Me-Pro ND NR    12 
DMP ND NR    10 
N-Me-Leu ND NR    8 
Aah ND NR    8 
Ala
† ND NR    8 
Gly
†
 ND NR       11 
aFrom Ref. 15 *Wild-type recovery experiment incorporating Pro using non-canonical 
amino acid mutagenesis. †Conventional mutants. NR, no response. ± SEM 
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3-methylproline (3-Me-Pro), 3,4-dehydroproline (dhP), N-methylalanine (N-Me-Ala), 2-
methylproline (2-Me-Pro), 5,5-dimethylproline (DMP), lactic acid (α-hydroxyalanine, or 
 
Figure 4.2. Dose-response curves for non-canonical amino acids incorporated at P143 
in the 5-HT3AR. Each is compared to the wild-type recovery experiment, P143Pro. ± SEM 
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Aah), and N-methylleucine (N-Me-Leu). The dose-response relationships for the amino 
acids successfully incorporated are provided in Figure 4.2. Each is compared to the 
positive control “P143Pro,” for which responses were very nearly identical to those 
observed from expression of wild-type 5-HT3ARs. All but the latter four non-canonicals 
(Figure 4.3) gave robust responses upon expression in Xenopus laevis ooctyes. A range 
effects was observed for the different non-canonical amino acids, spanning a ~5-fold 
decrease in EC50 for 3-Me-Pro to a ~4-fold increase in EC50 for Mor.  
When considering the different chemical features of these amino acids in relation 
to receptor function (or lack thereof), no clear pattern is immediately obvious. There are, 
however, some general inferences that can be made. In the case of the non-functional amino 
acids 2-Me-Pro, DMP, and N-Me-Leu, we note the common feature of branched side 
chains, which we speculate may result in improper folding/trafficking due to steric 
constraints in this region of the protein. Nevertheless, the branched 3-Me-Pro yielded 
functional receptors, so the exact placement of the methyl groups in these amino acids may 
be important. The α-hydroxy analogue of alanine, Aah, also did not yield functional surface 
expression of 5-HT3ARs, which implies that simply removing the ability of Ala to H-bond 
donate via its backbone amide is insufficient to recapitulate the required properties of 
proline at this position (recall that P143A was also nonfunctional). 
 
Figure 4.3. Non-canonical amino acids that did not yield functional receptors upon 
attempted incorporation in place of 5-HT3AR P143. 
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A possible explanation of the data from the functional mutants is that a cis peptide 
bond may be a structural requirement at this position in the 5-HT3AR. As mentioned 
previously, prolyl peptide bonds have a greater intrinsic propensity to exist in the cis 
conformation than the other naturally-occurring amino acids.17 Likewise, all of the non-
canonical analogues successfully incorporated have higher intrinsic cis biases than natural 
amino acids other than proline.15,19,21–23 Many pLGIC structures depict the peptide bond to 
this proline in this cis conformation, and indeed there is an undeniable correlation between 
high structural resolution and assignment of a cis peptide bond across all pLGIC structures 
currently in the Protein Data Bank  (see section 3.3.2, Figure 3.6 for a full discussion of 
the structural data regarding this proline in pLGICs). 
 
Figure 4.4. Relationship between cis bias and change in EC50 for non-canonical 
amino acids incorporated in place of the Cys-loop proline. The data for the 5-HT3AR 
is shown in blue and that of the muscle-type nAChR (previously-reported15) is shown 
in red. Increased cis bias does not correlate closely with decreased EC50 for substitutions 
in the 5-HT3AR, even for the simple series of Pro, Pip, and Aze (R
2 = 0.65).  
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A plot of cis 
preference versus relative 
EC50, however, does not 
correlate especially well (R2 
= 0.65 for the simplest series 
Pro, Aze, Pip, which differ 
only in ring size; Figure 4.4) 
and P143 is in the trans 
conformation in all 5-HT3AR 
structures currently 
available.24–27 However, it is possible that the lower resolution of the 5-HT3AR structures 
may have resulted in an inaccurate representation.  
These data differ from those previously obtained from experiments in the muscle-
type nAChR where the cis preference strongly correlated (R2 = 0.99; Figure 4.4).15 Other 
proline analogous did not fit the trend in this analysis, but these could be largely explained 
if hydrophobicity was also considered. For the 5-HT3AR, hydrophobicity does not seem a 
likely explanation, as a plot comparing EC50 versus the side chain log(P) (calculated in 
SPARTAN14) did not indicate a significant correlation (Figure 4.5). Nevertheless, given 
that functional surface expression of 5-HT3ARs occurred only when P143 was replaced by 
non-canonical amino acids having higher intrinsic cis biases than naturally-occurring 
amino acids other than Pro, it is possible that, despite the relatively poor correlation, a cis 
peptide bond is required at this position, but that it is not the only important aspect of 
proline at this position. 
 
Figure 4.5. Lack of correlation between changes in 
EC50 and log(P) of non-canonical substitutions of 
P143 in the 5-HT3AR. Data ± SEM 
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4.3.2 Investigation of the electrostatic network within the interfacial region of the 5-HT3AR 
Another highly-conserved feature of the interfacial region of pLGICs is an 
extensive electrostatic network of amino acid residues side chains that bridge interactions 
between secondary structures closely implicated in receptor gating.1,2 Interactions between 
residues within this electrostatic network have been studied extensively across different 
members of the pLGIC superfamily, with differing and sometimes contradictory results.28–
36 
In the 5-HT3AR, several interactions between the pre-M1 arginine (R218) and 
nearby electron-rich residues are apparent (Figure 4.6).25 Specifically, it appears from this 
structure25 and other 5-HT3AR structures
24,26,27 that interactions exist between the R218 
side chain and the side chains of E53 (ß1-ß2 loop), D145 (Cys-loop), and E186 and W187 
(ß8-ß9 loop). We have built off of a limited amount of previous experimental work on this 
region of the 5-HT3AR
29 to define the 
contributions of interactions within 
this electrostatic network to receptor 
gating in the 5-HT3AR.  
The results from this line of 
investigation are tabulated in Table 
4.2 and dose-response curves for 
functional mutants are provided in 
Figure 4.7. Unfortunately, mutations 
to R218 and D145 did not yield 
measurable responses, consistent 
 
Figure 4.6. Electrostatic network of residues 
at the ECD-TMD interface of the 5-HT3AR. 
P143 is also shown for context. Atoms are 
colored by element: yellow, carbon; red, oxygen; 
blue, nitrogen. (PDB ID 6HIS)25 
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with previous results.29 We were nonetheless able to investigate the electrostatics of this 
region by mutating E53, E186, and W187. 
It was previously observed that mutating E53 to Ala, Cys, or Arg resulted in no 
interpretable response.29 We instead tried subtler mutations to probe the relevant steric and 
electrostatic contributions of this residue, although we also were able to express functional 
5-HT3ARs with a dramatic mutation, E53L (Table 4.2). Much to our surprise, all mutations 
to E53 intended to impair the interaction between this residue and R218 led to decreases in 
5-HT EC50 values of the mutant 5-HT3ARs. This is reflected in leftward shifts in the dose-
response relationships of E53 mutants relative to wild-type (Figure 4.7A). Thus it appears 
that, in a general sense, weakening the interaction between E53 and R218 enhances 
receptor gating. This enhanced gating may result from increased motional freedom of the 
ß1-ß2 loop, which has been shown to undergo rearrangements during the gating 
process.1,2,25  
Table 4.2. 
Functional consequences of mutations to the interfacial region of the 5-HT3AR. 
Mutation(s) EC50 (µM) nH |Imax|(µA) Fold N |ΔΔG|† 
- 1.3 ± 0.03 2.4 ± 0.11 1.0 - 78 1.0 21   
E53D 0.16 ± 0.01 2.8 ± 0.26 0.26 - 11 0.13 11   
E53Q 0.21 ± 0.01 2.9 ± 0.28 2.8 - 19 0.17 13   
E53L 0.05 ± 0.01 1.6 ± 0.24 0.07 - 1.1 0.041 9   
E53Nha 0.23 ± 0.005 3.7 ± 0.25 0.29 - 2.2 0.19 6   
E186D 3.6 ± 0.07 2.4 ± 0.08 0.54 - 69 2.9 14   
E186Nha 1.4 ± 0.10 2.7 ± 0.50 0.10 - 0.47 1.2 5   
W187F
4
Trp 1.1 ± 0.07 1.4 ± 0.09 0.11 - 0.79 0.87 6   
E53D E186D 0.15  ± 0.01 1.7  ± 0.24 0.69 - 1.4 0.12 6 0.67 
E53D P143Pip 0.13 ± 0.001 3.1 ± 0.11 2.7 - 6.5 0.10 8 0.39 
D145N NR    15   
R218A NR    3   
R218K NR       7   
 †kcal•mol-1. NR, no response. ± SEM 
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The gain of function observed 
for the variant E53L was particularly 
pronounced: this receptor had a ~25-
fold lower 5-HT EC50 than the wild-
type 5-HT3AR. Mutating the native 
glutamate to leucine is expected not 
only to abrogate salt-
bridging/hydrogen bonding to this 
residue, but also to introduce a 
substantial amount of steric bulk not 
present in the planar carboxyl side-
chain. Thus, this is the most-
perturbing mutation we employed at 
this site, consistent with perturbations 
of interactions with this residue 
resulting generally in enhanced 
receptor gating. We also note that the 
E53L mutation resulted in a dramatic 
reduction in the macroscopic 
deactivation rate of the mutant 5-HT3ARs, evident in a slowing of the return to baseline cell 
potential upon washout of 5-HT (Figure 4.8). This would be consistent with a substantial 
stabilization of the open state, resulting in an increased energetic barrier between the open 
state and resting state of the receptor. 
 
Figure 4.7. Dose-response curves for A, E53 
single-mutants, B, E186 and W187 single-
mutants, and C, double-mutants in the 
interfacial region of the 5-HT3AR. ± SEM 
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We sought to further assess 
the role of E53 in 5-HT3AR gating by 
using non-canonical amino acid 
mutagenesis to incorporate the amino 
acid γ-nitrohomoalanine (Nha). This 
non-canonical amino acid has been 
used previously to probe interactions 
with glutamate residues.30,37,38 As illustrated by the electrostatic potential map in Figure 
4.9A, Nha is a nonpolar isostere of glutamate, having a nitro group in place of the glutamate 
carboxyl. Thus, Nha removes the polar carboxyl group of glutamate while otherwise not 
altering the sterics of the amino acid. Akin to the results for natural amino acids, the 
E53Nha mutation resulted in a ~5-fold decrease in 5-HT EC50 relative to wild-type. 
Unfortunately, we were unable to run the appropriate positive control (incorporating 
glutamate using the non-canonical strategy) due to poor tRNA quality, which led to low 
signals.  
To further investigate the electrostatics in this region, we introduced mutations to 
perturb interactions to E186 (Figure 4.7B). It had been previously observed that 
substituting this residue with glutamine (E186Q) caused no meaningful change in 5-HT3AR 
function.39 We tried two other substitutions: E186D and E186Nha. The mutation E186D 
resulted in a modest ~3-fold loss-of-function, contrasting with the gains of function seen 
for E53 mutations. Employing the nonpolar glutamate isostere Nha in place of E186, we 
observed near wild-type responses to 5-HT. Thus, it appears that the exact positioning of 
the E186 side chain is more important for proper receptor gating than the electron-rich 
 
Figure 4.8. Comparison of electrophysiolog-
ical trace shapes for wild-type and E53L 5-
HT3ARs at 5-HT concentrations eliciting a 
maximal response. 
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carboxyl group. But even in the case of E186D, the loss of function is meaningful but not 
particularly substantial.  
Further, we probed the functional relevance of the electron-rich indole ring of 
W187 via non-canonical amino acid mutagenesis to the fluorinated tryptophan analog, 
F4Trp. Substitution of the indole ring with electron-withdrawing fluorine atoms reduce the 
electron density of the aromatic ring to the point that it has nearly-neutral electrostatic 
potential in the tetrasubstituted F4Trp (Figure 4.9B). Thus, substituting W187 with F4Trp 
should attenuate the cation-π interaction with R218 suggested by 5-HT3AR structures. 
Upon mutating W187 to F4Trp, we observed a 5-HT EC50 very close to that of wild-type 
5-HT3ARs (Table 4.2; Figure 4.7B). This result suggests either that a cation-π interaction 
does not exist between these residues, or perhaps that there is a cation-π interaction but it 
is not functionally relevant. Recent 5-HT3AR structures have suggested that the important 
feature of W187 is its steric bulk, 
contributing to a hydrophobic 
“sandwich” around the Cys-loop, 
especially P143.25  
Finally, we sought to examine 
functionally-relevant interactions 
between residues by means of mutant 
cycle analysis. Given that the most 
dramatic EC50 shifts were seen for the 
E53 mutants, we performed mutant 
cycles between E53D and mutations 
 
Figure 4.9. Electrostatic potential maps 
comparing side chain groups of A, glutamate 
to Nha, and B, tryptophan to F4Trp. 
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to E186 and P143. The results are summarized in Table 4.2 and dose-response 
relationships are provided in Figure 4.7C. The coupling energies observed were 
0.67kcal•mol-1 for the E53D E186D double mutant and 0.39kcal•mol-1 for the E53D 
P143Pip double mutant. As mentioned in Chapter 1, our criterion for a “meaningful” 
coupling energy is 0.40kcal•mol-1, representing a two-fold deviation from purely additive 
effects. Thus, it appears that E53D and E186D cooperate meaningfully in 5-HT3AR gating, 
but the coupling energy for the E53D P143Pip mutant pair is just short of what we would 
consider to be meaningfully coupled. There is substantial room for interpretation here, but 
it would appear in both mutant cycles that the effects of the mutations are somewhat 
dependent, but not tightly cooperative in the gating mechanism. This is surprising given 
the close proximity between these residue pairs and the observation in 5-HT3AR structures 
that E53 and E186 both interact directly with R218.24–27 One could speculate that there are 
compensatory effects at play, especially considering the opposite effects of E53 and E186 
mutations on receptor function.  
4.3.3 Contribution of the M2-M3 loop residue T280 to 5-HT3AR gating 
The M2-M3 loop is another secondary structure in the interfacial region of pLGICs 
closely involved in the gating mechanisms of pLGICs.1,2 While there have been many 
insights into functional roles of residues in the M2-M3 loop, the 5-HT3AR is the only 
pLGIC for which it has been explicitly shown that a proline residue in the M2-M3 loop 
(P281) undergoes cis/trans isomerization about the peptide bond during activation.21 Upon 
incorporation of non-canonical proline analogues with varying intrinsic propensities for 
cis/trans peptide bonds, a linear correlation was observed between changes in EC50 and the 
cis/trans biases of the amino acids incorporated at P281.21  
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Herein we sought to identify other features of the M2-M3 loop as they relate to 
cis/trans isomerization of P281, and 5-HT3AR gating as a whole. It was previously 
discussed that part of the motivation behind examining cis/trans bias as it relates to the 
conserved Cys-loop proline, P143, was that the residues immediately flanking P143 are 
both phenylalanine residues in the 5-HT3AR, and that the presence of aromatic amino acids 
next to proline residues in the primary sequence greatly increases the propensity for those 
prolyl peptide bonds to exist in the cis conformation.18–20 The residues on either side of 
P281 in the 5-HT3AR are T280 and L282, which is perhaps surprising given that P281 has 
been shown to cis/trans isomerize but lacks adjacent aromatics whereas P143 does not 
clearly cis/trans isomerize (see section 4.3.1) but has aromatics on both sides. We therefore 
attempted to modulate the cis/trans bias of P281 via aromatic substitutions to the adjacent 
residues. 
 Table 4.3 
 Effects of single mutations to T280 in the M2-M3 loop of the 5-HT3AR. 
Mutation EC50 (µM) nH |Imax|(µA) Fold N 
- 1.3 ± 0.03 2.4 ± 0.11 1.0 - 78 1.0 21 
T280Y 0.064 ± 0.003 2.2 ± 0.19 0.46 - 50 0.051 17 
T280MeOThr 0.21 ± 0.01  4.3 ± 0.41  0.09 - 5.9 0.17 24 
T280A 0.26 ± 0.01 2.9 ± 0.23 2.8 - 65 0.21 12 
T280F 0.29 ± 0.01 2.8 ± 0.17 0.28 - 3.2 0.23 12 
T280V 0.32 ± 0.01 3.5 ± 0.26 1.0 - 39 0.26 11 
T280S 0.48 ± 0.01 4.0 ± 0.18 8.5 - 27 0.38 10 
T280Thr 1.2 ± 0.04 1.9 ± 0.12 0.06 - 1.2 1.0 15 
T280-4-CH
3
Phe NR    14 
T280-4-FPhe NR    12 
T280-4-OMePhe NR    12 
T280-4-BrPhe NR    5 
T280-4-CNPhe NR    7 
T280Cha NR       10 
 NR, no response. ± SEM 
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The results from the T280 mutations are the most noteworthy (Table 4.3; Figure 
4.10). Initial results seemed to suggest that the strategy had worked as planned: substituting 
T280 with phenylalanine (T280F) or tyrosine (T280Y) caused ~4-fold and ~20-fold 
decreases in 5-HT EC50, respectively, consistent with there being an isomerization from 
the trans conformation to the cis conformation upon receptor activation. It is also worth 
noting that tyrosine is expected to increase the cis preference of adjacent prolyl peptide 
 
Figure 4.10. Dose-response curves of 5-HT3ARs with the indicated side-chain 
substitutions at T280. ± SEM 
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bonds to a greater extent than 
phenylalanine, which would be 
consistent with the greater gain-of-
function we observed for T280Y 
versus T280F.18–20 Interestingly, 
there was a marked change in the 
macroscopic 
activation/deactivation rates for T280Y receptors (Figure 4.11), similar to what was 
observed previously for the mutant E53L which had a similarly large gain-of-function. 
Comparing the T280Y electrophysiological traces to those of wild-type 5-HT3ARs, the 
rates of activation and deactivation are both reduced, suggesting perhaps a stabilization of 
the open state as well as either a stabilization of the resting state or a destabilization of the 
transition state. In the absence of single-channel electrophysiological data, it is impossible 
to tell exactly how the energetics of different receptor states have been affected.  
As negative controls, we characterized the function of the mutants T280A, T280V, 
and T280S. All of these amino acids lack the aromaticity of Phe and Tyr but resemble Thr 
in other ways. Val is sterically similar to Thr but lacks the ability to hydrogen bond; Ser 
preserves hydrogen bonding but has reduced steric volume; Ala both reduces sterics and 
lacks the ability to hydrogen bond. These negative controls were expected to give 
functional responses that were loss of function or near wild-type, however all three 
mutations gave gains of function comparable to that observed for T280F (Table 4.3; 
Figure 4.10). Thus. it appears in a general sense that perturbing interactions to the T280 
 
Figure 4.11. Comparison of electrophysiolog-
ical trace shapes for wild-type and T280Y 5-
HT3ARs at 5-HT concentrations eliciting a 
maximal response. 
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side chain – either by way of removing the hydroxyl group or reducing steric bulk – result 
in enhanced receptor gating.  
The large reduction in EC50 for T280Y was intriguing, and the possibility that this 
mutation was having multiple effects including increasing the cis bias of the P281 peptide 
bond was not patently excluded by the above analysis, so we attempted substitution of 
T280 with a variety of non-canonical amino acids to gain more insight into the role of this 
residue. It has been shown that the electron density of the aromatic ring adjacent to a proline 
correlates with increased proportions of the cis prolyl peptide bond,20 so we attempted 
incorporation of a variety of 4-substituted phenylalanine analogs via non-canonical amino 
acid mutagenesis. The amino acids we attempted to incorporate are shown in Figure 4.12. 
Unfortunately, none of these non-canonicals incorporated well-enough in place of T280 in 
order for us to measure electrophysiological responses. We did, however, successfully 
incorporate O-methylthreonine (MeOThr) and the positive control, threonine, via the non-
canonical amino acid mutagenesis strategy. The resultant dose-response curves are shown 
in Figure 4.10B. Incorporation of the wild-type threonine gave responses very close to 
those of unmutated wild-type receptors, and incorporation of MeOThr led to a ~6-fold 
decrease in the EC50 of 5-HT. Thu,s methylating the T280 side-chain hydroxyl group, both 
removing the ability to hydrogen-bond donate and increasing steric bulk, led to a gain-of-
 
Figure 4.12. Side chains of non-canonical amino acids residues that yielded no 
measurable response upon attempted incorporation in place of T280.  
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function, in line with every other substitution of T280 for which we could measure 
responses.  
Given the lack of conclusive results regarding the effects of the above-described 
T280 mutations on cis/trans isomerization of P281, we next turned to a different strategy 
involving mutant cycle analysis between T280 mutations and P281 mutations. We 
reasoned that if a mutation to T280 results in a gain-of-function by means of increasing the 
cis bias of P281, then a P281 mutation that increases the intrinsic cis bias of the peptide 
bond should have non-additive effects in combination with the T280 mutation, reflect in a 
large |G| (at least >0.40kcal•mol-1). The most obvious candidate T280 mutation for the 
mutant cycle analyses was T280Y, since this mutation caused a large gain-of-function that 
could result in part from increasing the cis bias of P281. When considering the mutation to 
introduce at P281, the best candidates would be 5,5-dimethylproline (DMP) or 5-
tertbutylproline (Tbp), as these proline analogs were previously reported to have strong cis 
biases and accordingly cause large decreases in 5-HT EC50 when incorporated at P281 in 
the 5-HT3AR.
21 Unfortunately, however, Tbp tRNA was not readily available to us and 
attempted incorporation of DMP led to no measurable response in our hands. We did, 
 Table 4.4 
 Substitutions of P281 and mutant cycles between T280Y and P281 mutations. 
Mutation(s) EC50 (µM) nH |Imax|(µA) Fold N |ΔΔG|† 
P281Pro 1.4 ± 0.007 4.0 ± 0.08 1.8 - 9.0 1.0 17   
P281Mor 0.57 ± 0.04 1.7 ± 0.17 0.10 - 0.15 0.46 5   
P281trans-F-Pro  1.1 ± 0.03 3.3 ± 0.31 0.14 - 11 0.84 11   
P281cis-F-Pro 0.83 ± 0.06 3.1 ± 0.53 0.49 - 9.0 0.67 13   
T280Y P281Pro 0.067 ± 0.004 1.6 ± 0.10 0.03  - 4.2 0.05 23 0.057 
T280Y P281Mor 0.052 ± 0.005 1.9 ± 0.32 0.14 - 0.71 0.037 6 0.29 
T280Y P281trans-F-Pro 0.040 ± 0.002 2.1 ± 0.23 0.08 - 6.1 0.029 13 0.17 
T280Y P281cis-F-Pro 0.031 ± 0.004 1.5 ± 0.26 1.1 - 3.0 0.51 10 0.11 
†kcal•mol-1. ± SEM 
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however, have ready access to amber-suppressing tRNA aminoacylated with Mor. This 
proline analog, while not included in the initial investigation of cis/trans isomerization at 
P281 in the 5-HT3AR, has been shown to have increased cis bias relative to proline in a 
model peptide system.15  
The overall pharmacological parameters for P281Mor and the positive control 
P281Pro are provided in Table 4.4 and dose-response curves are illustrated in Figure 4.13. 
Substitution of P281 with Mor led to a ~2-fold gain-of-function relative to the wild-type 
recovery experiment, the dose-response relationship of which was in line with the wild-
type 5-HT3AR. Plotting the G(cis-trans) value for Mor versus the G(EC50) for the 
change in receptor function reveals a very close match with the previously-reported results 
for non-canonical proline analogs at P281 (Figure 4.14).21 Although the G(cis-trans) 
value for Mor was determined using a different method than those reported in the initial 
investigation,15,21 G(cis-trans) values for non-canonical proline analogs in both studies 
were indexed to that of proline itself, which was set to 0 kcal•mol-1. Thus, while not a 
perfect representation, this analysis 
supports the conclusion that the gain-
of-function of P281Mor results 
primarily from an increased cis bias of 
the peptide bond at that position. 
We next combined T280Y and 
P281Mor in a mutant cycle analysis. 
The results again are tabulated in 
Table 4.4 and dose-response curves 
 
Figure 4.13. Dose-response curves for a 
mutant cycle between T280Y and P281Mor 
in the 5-HT3AR. ± SEM 
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are illustrated in Figure 4.12. 
Combining the mutations yielded 
receptors with a 5-HT EC50 value of 
0.052 ± 0.005µM, a slight gain-of-
function relative to the positive 
control T280Y P281Pro, the dose-
response relationship of which was 
closely in line with T280Y 5-HT3AR. 
Thus the effects were mostly additive, 
with a |G| of 0.29kcal•mol-1, 
falling short of our criterion for meaningful coupling.  
To take one last look at the potential role of the T280Y mutation in modulating the 
cis/trans bias of the P281 peptide bond, we performed mutant cycles between T280Y and 
the non-canonical proline analogs cis-F-Pro and trans-F-Pro at P281. The rationale behind 
this line of experimentation is illustrated in Figure 4.15: cis-F-Pro and trans-F-Pro are 
known to affect the ring “pucker” of the pyrrolidinyl group of these non-canonicals, with 
cis-F-Pro favoring the Cγ-endo pucker and trans-F-Pro biasing toward the Cγ-exo pucker.20 
In the case of an adjacent tyrosine residue, as in T280Y 5-HT3ARs, one would expect cis-
F-Pro to promote a conformation conducive to polar-π interactions between hydrogen 
atoms of the pyrrolidinyl group and the pi-face of the tyrosine phenol in the presence of a 
cis peptide bond at the 281 position, while the pucker of trans-F-Pro would both reorient 
the pyrrolidinyl hydrogens away from the tyrosine phenol and cause repulsive interactions 
between the fluorine atom and the negative electrostatic potential of the aromatic. Thus we 
- 2 . 5 - 2 . 0 - 1 . 5 - 1 . 0 - 0 . 5 0 . 0
- 3
- 2
- 1
0
1


G
(
E
C
5
0
)
 (
k
c
a
l•
m
o
l-
1
)
  G  ( c i s - t r a n s )  ( k c a l • m o l
- 1
)
 
Figure 4.14. The 5-HT3AR mutation 
P281Mor. The newly-reported datum (green) 
aligns closely with previously-reported data 
regarding cis/trans bias at P281 in the 5-
HT3AR.
21 ± SEM 
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would expect the effects of T280Y and P281cis-F-Pro to be superadditive, while the 
P281trans-F-Pro mutation should mitigate the gain-of-function of T280Y.  
The observed results were not consistent with our predictions. Tabulated results are 
given in Table 4.4 and dose-response data are shown in Figure 4.16. In either mutant cycle, 
the values for |G| are well below our criterion for meaningful; thus it does not appear 
that introducing a fluorine on the proline pyrrolidinyl ring has any effect on the gain-of-
function caused by T280Y.  
In our last attempt to understand the effects of the T280 mutations examined herein, 
we made substitutions to L282, the next residue in the primary sequence after P281. In the 
5-HT3AR crystal structure (PDB ID 4PIR) and one 5-HT3AR cryo-EM structure (PDB ID 
6HIS), the T280 side-chain hydroxyl hydrogen-bonds to either the backbone amide NH of 
L282 or the backbone amide carbonyl contributed by P281 (Figure 4.17). While the state 
of the receptor in the crystal structure is unclear, the cryo-EM structure has been assigned 
 
Figure 4.15. Rationale behind mutant cycle analyses between T280Y and cis/trans-
F-Pro substitutions at P281. The cis peptide bond is highlighted in red. A, cis-F-Pro 
favors the Cγ-endo pucker, which should enable favorable interactions between the 
pyrrolidinyl hydrogens and the π-face of T280Y in the cis conformation of the peptide 
bond at the 281 position. B, trans-F-Pro favors the Cγ-exo pucker, which should 
disfavor a cis conformation of the 281 peptide bond. 
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to the closed state of the 5-HT3AR.
24,25 Notably, the gains of function associated with 
disrupting the ability of T280 to hydrogen bond we report herein would be consistent with 
the existence of this hydrogen bond to the backbone stabilizing a closed state of the 
receptor.  
To examine the potential role of this hydrogen bond in receptor gating, we intended 
to attempt a mutant cycle between mutations that ablate the ability of T280 to hydrogen 
bond and abolish/weaken the hydrogen bonding capacity of the L282/P281 backbone 
amide bond. The latter can be accomplished via non-canonical amino acid mutagenesis 
employing 2-hydroxy-4-methylpentanoic acid (α-hydroxyleucine, or Lah), the α-hydroxy 
acid analog of leucine. This substitution would abolish hydrogen bonding between the 
T280 side-chain hydroxyl and the L282 backbone NH (Figure 4.17A) or would greatly 
weaken the hydrogen bond to the P281 backbone carbonyl (Figure 4.17B), as ester 
carbonyls are much poorer H-bond acceptors than amide carbonyls. This is an established 
means of probing main-chain hydrogen bonding interactions.40 
 
Figure 4.16. Dose-response curves for mutant cycles between T280Y and A, 
P281cis-F-Pro and B, P281trans-F-Pro. ± SEM 
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Thus we introduced the mutations L282Lah and the positive control L282Leu using 
the non-canonical amino acid mutagenesis strategy. The results are provided in Table 4.5 
and dose-response curves are given in Figure 4.18. The L282Lah mutation did not result 
in a meaningful change in receptor function, so it appears that there is no functionally-
relevant interaction to the peptide backbone at this position. Therefore, we did not proceed 
with a mutant cycle with any T280 mutations.  
Lastly, with a plasmid encoding m5-HT3A L282TAG and amber-suppressing 
tRNAs aminoacylated with aromatic amino acids at our ready disposal, we sought to assess 
 
Figure 4.17. Hydrogen bonding between the T280 side-chain hydroxyl and the 
peptide backbone suggested by A, the 5-HT3AR crystal structure (PDB ID 4PIR)
24 and 
B, a 5-HT3AR cryo-EM structure (PDB ID 6HIS).
25 
Table 4.5 
Mutations to L282 in the 5-HT3AR. 
Mutation EC50 (µM) nH |Imax|(µA) Fold N 
L282Leu 1.3 ± 0.02 3.4 ± 0.16 5.5 - 36 1.0 19 
L282Lah 1.7 ± 0.03 3.4 ± 0.19 0.44 - 31 1.3 24 
L282Phe 0.78 ± 0.02 3.7 ± 0.21 3.2 - 12 0.62 8 
L282Trp 1.4 ± 0.03 3.9 ± 0.30 0.32 - 7.3 1.1 8 
± SEM 
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the generality of the results 
observed from aromatic 
substitutions at T280 by using 
the non-canonical amino acid 
mutagenesis method to 
conveniently introduce different 
aromatic amino acids in place of 
L282. In this way, we introduced the mutations L282F and L282W (Table 4.5; Figure 
4.18). There was a small gain-of-function for the L282F mutation that nonetheless fell short 
of our “meaningful” criterion of a two-fold change in function, and function of the L282W 
receptors was very nearly identical to wild-type. Thus it does not appear that the results 
from aromatic substitutions to T280 extend to the other residue neighboring P281, 
providing further evidence that we have not successfully modulated cis/trans bias at P281 
via aromatic substitutions to T280.  
4.3.4 Long-range interactions between T280 and other 5-HT3AR residues 
The gating process of the 5-HT3AR and pLGICs at large involves allosteric 
communication of a ligand binding event in the extracellular domain to the membrane-
spanning channel pore, around 60Å away.1,2 Thus there must be cooperation across this 
entire distance to bring about the requisite structural rearrangements that lead to channel 
opening. We therefore sought to use mutant cycle analysis to evaluate the energetic 
coupling of T280 mutations to mutations of other residues studied herein that are not in 
direct contact with T280. 
 
Figure 4.18. Dose-response curves for L282 
mutations in the 5-HT3AR. ± SEM 
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Figures 4.19A-F compare the dose-response curves of receptor variants with a 
mutation at T280 and another mutation in the interfacial region to those of wild-type 
receptors and those of the cognate single-mutants. The pharmacological parameters of the 
 
Figure 4.19. Dose-response curves for mutant cycles between T280Y and other 
residues involved in 5-HT3AR gating. ± SEM 
102 
 
double-mutants, including |G| values, are tabulated in Table 4.6. T280Y does not couple 
appreciably to P143Pip or P143Mor. T280Y does couple weakly to E186D (|G| = 0.43 
kcal•mol-1), but couples much more strongly to E53D (|G| = 1.2 kcal•mol-1).  
Given the observed coupling between E53D and T280Y, we wanted to test the 
generality of this coupling by combining E53D with other T280 mutations. While we do 
not consider small (<0.40 kcal•mol-1) differences in |G| values to be worth discussing, 
it is of note that E53D is more energetically coupled to aromatic substitutions at T280 than 
to T280V (Table 4.6). In particular, the single-mutants T280V and T280F result in very 
comparable gains-of-function relative to wild-type, yet T280V couples to E53D with a 
|G| of only 0.81 kcal•mol-1 while T280F couples to E53D with a |G| of 1.5 kcal•mol-
1. 
To probe for long-range allosteric cooperation between T280 and residues that may 
be involved in early steps in receptor gating, we performed mutant cycle analyses between 
T280Y and the mutations T152V and N101K. In Chapter 2, we demonstrated allosteric 
communication between these two mutations and the channel pore mutation T6’S, 
establishing a role for these residues in receptor gating. Here, we report energetic coupling 
 Table 4.6 
 Mutant cycles between T280Y and other residues involved in 5-HT3AR gating. 
Mutation(s) EC50 (µM) nH |Imax|(µA) Fold N |ΔΔG|
† 
P143Pip T280Y 0.025 ± 0.001 1.3 ± 0.09 0.06 - 0.44 0.02 11 0.13 
P143Mor T280Y 0.19 ± 0.01 4.0 ± 0.41 0.06 - 0.94 0.15 12 0.30 
E186D T280Y 0.10 ± 0.004 2.6 ± 0.23 10 - 30. 0.08 12 0.43 
E53D T280V 0.16 ± 0.01 1.5 ± 0.10 0.05 - 0.20 0.13 11 0.81 
E53D T280Y 0.074 ± 0.004 1.4 ± 0.09 0.15 - 1.3 0.06 12 1.2 
E53D T280F 0.51 ± 0.05 1.4 ± 0.16 0.08 - 0.61 0.41 10 1.5 
N101K T280Y 1.3 ± 0.08 1.5 ± 0.11 1.1 - 37 1.1 9 0.36 
T152V T280Y 0.087 ± 0.01 1.6 ± 0.16 0.05 - 0.48 0.069 9 0.95 
 †kcal•mol-1. ± SEM 
103 
 
between T152V and T280Y and a lack of meaningful energetic coupling between N101K 
and T280Y (Table 4.6).  Full dose-response curves are shown in Figure 4.19G-H. It 
appears from these results that T152V affects gating via a pathway that is affected by 
T280Y, whereas the effects of N101K and T280Y are more independent.  
4.4 Conclusions 
Herein we have used mutagenesis to conduct an investigation of 5-HT3AR gating in 
regard to amino acid residues in the interfacial region between the extracellular domain 
and transmembrane domain of this receptor. Using mutant cycle analysis, we have 
quantified energetic couplings between pairs of mutations that affect the gating process in 
dependent ways.  
Mutating the conserved Cys-loop proline, P143, to a series of non-canonical amino 
acids, we report a lack of evidence for cis/trans isomerization of the P143 peptide bond 
during activation of the 5-HT3AR, although our results suggest that a cis peptide bond or at 
least a substituted amide nitrogen may be critical features of this residue for receptor 
function. These results are somewhat in line with those observed in other pLGICs, namely 
GLIC,13 ELIC,14 and the muscle-type nAChR,15 however there do seem to be differences 
in regard to the exact features of this proline residue that influence function in these 
different receptors.  
We have further investigated interactions between residues comprising the 
electrostatic network within the interfacial region of the 5-HT3AR, which is largely 
conserved across the pLGIC superfamily.1,2 Of particular note is the ß1-ß2 loop residue, 
E53, the mutation of which leads to receptor variants with up to 25-fold increased 
sensitivity to 5-HT. Via mutant cycle analysis, we establish a functionally-relevant 
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interaction between E53 and the nearby E186, the mutation of which impairs receptor 
function. Other residues in this network include W187, D145, and R218. Being the 
apparent linchpin of the electrostatic network (as evident in 5-HT3AR structures), we have 
identified no functional mutants of R218, in line with previous results.29 Likewise, D145 
appears to be critical for receptor function. Via non-canonical amino acid mutagenesis of 
W187 to F4Trp, we identify no functionally-relevant cation-pi interaction between this 
residue and R218.  
Lastly, we have conducted a thorough investigation into the role of the 5-HT3AR 
residue T280 in receptor gating. Initially trying to modulate cis/trans isomerization of P281 
by mutating T280 to aromatic residues, we identified a number of mutations that lead to 
gain-of-function phenotypes, of which that for T280Y was particularly pronounced. We 
employed mutant cycles to assess whether this gain-of-function resulted from effects on 
the cis/trans bias of P281 or from ablation of a nearby hydrogen bond, but ultimately have 
not identified the exact means by which T280Y and other mutations lead to gains of 
function. Mutant cycles between T280 mutations and more-distant residues have revealed 
that E53 and T152 are energetically coupled to T280 in the 5-HT3AR activation mechanism. 
4.5 Experimental Procedures 
4.5.1 Molecular biology 
The cDNA for the mouse 5-HT3R A subunit was in the pGEMhe vector. Site-
directed mutagenesis was performed using a QuikChange mutagenesis kit (Stratagene). For 
non-canonical amino acid mutants and conventional mutants generated by non-canonical 
amino acid mutagenesis, the site of interest was mutated to the TAG stop codon. cDNA 
was linearized using XhoI (New England Biolabs). Linearized DNA was purified using a 
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Qiaquick PCR Purification Kit (Qiagen) before performing an in vitro runoff transcription 
using a T7 mMessage mMachine kit (Ambion). The mRNA was purified using an RNEasy 
Mini Kit (Qiagen) and concentrations were quantified via UV-Vis spectroscopy (Nanodrop 
2000, ThermoFisher Scientific). cDNA was stored at -20ºC and mRNA was stored at -
80ºC. 
Hydroxy or 4,5-dimethoxy-2-nitrobenzyloxycarbonyl (NVOC) protected amino 
acid-dCA couples were enzymatically ligated to truncated 74mer THG73 tRNA as 
previously described.41,42 The 74mer tRNA was prepared using the Ambion 
T7MEGAshortscript kit by transcription from a modified DNA oligonucleotide template 
as described in the literature to enhance RNA transcript homogeneity.43 Crude tRNA-
amino acid or tRNA-hydroxy acid product was used without desalting, and the product was 
confirmed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry 
on a 3-hydroxypicolinic acid matrix. Deprotection of the NVOC group on the tRNA-amino 
acids was carried out by 5-min photolysis on a 1 kW xenon lamp with WG-335 and UG-
11 filters or for 2.5-min using a 1150mW 365nm LED (Thorlabs) immediately prior to 
injection. Either deprotection strategy yielded fully deprotected aminoacyl tRNAs as 
assayed by MALDI-TOF mass spectrometry.  
4.5.2 Protein expression in Xenopus laevis oocytes 
Stage V-VI oocytes of Xenopus laevis were harvested and injected with RNAs as 
described previously.42 For non-canonical amino acid mutagenesis experiments, each cell 
was injected with 25-100ng each of receptor mRNA and appropriate tRNA in 50nL of 
nuclease-free water approximately 48h before recording. Mutants yielding small responses 
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required 72h of incubation, with a second injection of mRNA and tRNA 48h before 
recording.  
As a negative control for non-canonical mutagenesis experiments at each site, 
unacylated full-length tRNA was co-injected with mRNA in the same manner as charged 
tRNA. These experiments yielded no measurable responses, or negligible responses for all 
sites. Wild-type recovery conditions (injecting tRNA charged with the appropriate amino 
acid to regenerate a wild type channel via non-canonical amino acid mutagenesis at a TAG 
stop codon) were injected alongside mutant non-canonical amino acid mutagenesis 
conditions as a positive control. 
For wild-type experiments and conventional mutants, the procedure varied 
depending on expression levels. For higher-expressing variants, each cell received a single 
injection of 1-25 ng of receptor mRNA dissolved in 50nL of nuclease-free water 
approximately 24 h before recording.  For lower-expressing variants, oocytes were injected 
up to twice – once at t = 0h and once more at t ≈ 24h – and incubated for a total of up to 
72h from the first injection. 
In all experiments, cells were incubated at 18ºC in ND96 (96mM NaCl, 2mM KCl, 
1mM MgCl2, 1.8mM CaCl2, and 5mM HEPES at pH 7.5) with 0.05mg/mL gentamycin 
(Sigma Aldrich), 2.5mM sodium pyruvate (Acros Organics), and 0.67mM theophylline 
(Sigma Aldrich). 
4.5.3 Whole-cell electrophysiological recording 
Electrophysiology and drug perfusion were performed at ambient temperature (20-
25ºC) using the OpusXpress 6000A (Axon Instruments) in two-electrode voltage clamp 
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(TEVC) mode. Oocytes were impaled with borosilicate glass pipettes filled with 3M KCl 
(R = 0.3 – 3.0MΩ) and clamped at a holding potential of -60mV. Data were sampled at 
125Hz. The running buffer was Ca2+-free ND96 (96mM NaCl, 2mM KCl, 1mM MgCl2, 
and 5mM HEPES at pH 7.5). Solutions of serotonin hydrochloride (Sigma Aldrich) were 
prepared 0-24h before recording from stock solutions stored at -80ºC.  
For dose-response experiments, cells underwent a 30s pre-wash in Ca2+-free ND96 
before 1mL of each concentration of drug (dissolved in Ca2+-free ND96) was applied for 
15s. Cells were then washed for 116s using Ca2+-free ND96 before subsequent doses. For 
slow-activating variants, 1mL of drug solution was applied for 15s and cells were incubated 
in the drug solution for an additional 15s before washout. For slow-deactivating variants, 
washout times were increased to 176s in between doses. The different procedure for slow 
activating/deactivating variants did not meaningfully change the overall dose-response 
relationships recorded versus the standard 15s application / 116s wash procedure.  
4.5.4 Data analysis 
Raw TEVC traces were prepared and analyzed in Clampfit 10.3 (Axon 
Instruments). Raw data were first filtered using a lowpass Gaussian filter at 1Hz. A 30s 
baseline was established prior to each drug application during which cells were 
continuously perfused with Ca2+-free ND96. The averaged current of the baseline was 
subtracted from the peak amplitude following each drug application in order to generate 
dose-response data.  
Dose-response data for individual concentrations were averaged, plotted, and fitted 
to the Hill equation I / Imax = 1 / (1 + (EC50 / [agonist]
nH) in Prism 7 (GraphPad), where 
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EC50 is the concentration for a half-maximal response, nH is the Hill coefficient, and I / Imax 
is the normalized response at a given drug concentration. For dose-response experiments, 
data were normalized to the maximum current observed.  
Coupling energies for double-mutant cycles were calculated using the formula G 
= -R*T*ln((EC50wt*EC50AB) / (EC50A*EC50B)), where R is the gas constant, T is 
temperature, A and B denote individual mutations, and AB denotes double mutant 
receptors. The value used for T was 293.15K.  
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Chapter 5: Investigations of Signaling via Estrogen Receptor α Using a 
Photocrosslinking Non-canonical Amino Acid* 
 
5.1 Abstract 
 The estrogen receptor α (ERα) is a transcription factor in the nuclear receptor 
superfamily, and is an important drug target for the treatment of various cancers. Much 
research into the activation mechanism of ERα has been done, but some inconsistencies 
have been reported between different systems. Moreover, the molecular details of how the 
intrinsically disordered N-terminal domain (NTD) of ERα contributes to receptor function 
are not well-characterized. Herein we have used photocrosslinking of non-canonical amino 
acids (NCAAs) incorporated site-specifically into ERα to study dimerization of the 
receptor (a critical step in transcriptional activation), and to scan for interactions between 
ERα and coregulatory proteins in a region of the NTD that is known to contribute to 
receptor function. The results of this study may inform future research using 
photoactivatable NCAAs for the study of ERα and other receptors. 
5.2 Introduction 
 Proteins in the nuclear receptor family of transcription factors play important roles 
in regulating the expression of genes.1 The estrogen receptor α (ERα) is a member of the 
nuclear receptor family and is involved in oncogenic signaling pathways that contribute to 
several different cancers, most notably breast cancer.2,3 ERα is a validated drug target, with 
antiestrogens like tamoxifen (TMX) being widely prescribed in the treatment and 
prevention of breast cancer.4,5 
                                                          
* This work was done in close collaboration with Stephen Grant, and was based on 
previous work by Dr. Matthew Rienzo. 
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 The overall mechanism of action of ERα was discussed generally in section 1.2, 
but we will reiterate key points and highlight more specific details here. ERα is a 
multidomain protein, with an intrinsically-disordered N-terminal domain (NTD), a DNA-
binding domain (DBD), a ligand-binding domain (LBD), and a “hinge domain” between 
the latter two.6–8 ERα natively responds to endogenous estrogens such as ß-estradiol (E2), 
which are agonists of this receptor. Binding of estrogen agonists in the LBD causes ERα 
to dissociate from a chaperone complex in the cytosol and to next dimerize and translocate 
to the nucleus, where it assembles along with coregulatory proteins and RNA polymerase 
into a transcriptionally-active complex. Recognition of estrogen response elements (EREs) 
via the ERα DBD guides the complex to regulate expression of the appropriate genes. 
 While the mechanism of action of ERα is straightforward in principle, there are a 
myriad of factors that can contribute to the differential activity of ERα in different cellular 
environments. The archetypal example of this comes from the observation that TMX, the 
widely-prescribed antiestrogen, has different effects in different tissue types: while TMX 
is antiproliferative in breast cancer cells, it has a proliferative effect in bone and uterus 
tissues.9,10 The action of ERα has been described as an “Ensemble Allosteric Model” in 
which the activity of the receptor can be modulated by variables such as type and 
accessibility of EREs, relative expression levels of coregulatory proteins, expression of 
different ERα splice variants, post-translational modifications of ERα, and intracellular 
conditions including pH and osmolyte levels.10,11 
Given the complexity of signaling through ERα, it would be useful to have a precise 
technique to investigate aspects of ERα activation and regulation involving protein-protein 
interactions, such as homodimerization and cofactor binding. Previous work in our lab by 
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Dr. Matthew Rienzo addressed this need, establishing the use of photocrosslinking non-
canonical amino acids (NCAAs) to study ERα homodimerization (DOI 
10.7907/Z9G44N8W). Using a modified procedure from the Krogsgaard group (New York 
University), Dr. Rienzo optimized expression via nonsense suppression (section 1.3; the 
“synthetase method”) of N-terminally eGFP-tagged human ERα containing single 
mutations to photoactivatable NCAAs in the LBD at the dimerization interface and 
demonstrated dose-dependent covalent crosslinking of ERα dimers in response to E2.   
Herein we have expanded on that work to demonstrate the dose-dependent 
dimerization of N-terminally eGFP-tagged ERα in response to (Z)-4-hydroxytamoxifen (4-
OHT), the active metabolite of TMX, and the selective estrogen receptor downregulator 
(SERD) ICI-182780, also known as fulvestrant.12,13 We have also applied the 
photocrosslinking strategy to probe for cofactor interactions in the ERα NTD and have 
identified several potential hits. This research adds to our collective understanding of ERα 
function, and may inspire future investigations of protein-protein interactions in nuclear 
receptors and other proteins.  
5.3 Results & Discussion 
5.3.1 Studying dimerization of ERα using photocrosslinking 
It is well-known that dimerization of ERα is essential for transcriptional activity, 
and that E2 induces dimerization of the receptor.6,14,15 Many studies have studied 
dimerization of purified ERα in vitro, however relatively few in vivo methodologies exist 
and all come with their own limitations.16–20 Considering the ability of ERα to behave 
differently in response to its cellular environment, it is especially important to be able to 
study ERα dimerization in vivo using methods that are minimally perturbing, such as 
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photocrosslinking of NCAAs.21 This strategy allows us not only to study protein-protein 
interactions in a more nearly native environment, but also to probe interactions site-
specifically at the resolution of individual residues.  
Previous efforts in our lab by Dr. Matthew Rienzo laid the groundwork for using 
photocrosslinking of NCAAs to study ERα dimerization. The NCAAs 4-
benzoylphenylalanine (Bpa) and 4-azidophenylalanine (N3Phe) (Figure 5.1) were used to 
probe several sites at the ERα dimerization interface contributed by the LBD. When 
irradiated with UV light, both of these NCAAs generate a radical species that will react to 
form a covalent crosslink with a broad range of functional groups, even including aliphatic 
C-H bonds. It was found that the substitutions T460Bpa and H516N3Phe gave robust 
crosslinking of the ERα dimer, and that dimerization increased with increasing 
concentrations of E2 in the cell culture medium. For the experiments described herein, we 
proceeded with the H516N3Phe substitution for studying dimerization, as the crosslinking 
reaction is more general for N3Phe than Bpa, and N3Phe is less sterically bulky than Bpa.
22 
The H516 site is depicted in Figure 5.2; this residue resides at the dimerization interface 
in the LBD of ERα.  
In collaboration with Stephen Grant, we first replicated the dose-dependent 
dimerization of eGFP-ERα H516N3Phe in response to E2. We expressed the mutant 
 
Figure 5.1. Photocrosslinking NCAAs used previously by our lab to study ERα 
dimerization. Only N3Phe was used in this study. 
116 
 
receptors in HEK293T cells, incubated with varying concentrations of E2, and 
subsequently irradiated whole cells for 20min with a 1150mW 365nm LED to generate our 
crosslinked species. Cells were then lysed in PBS containing 1% SDS, subjected to SDS-
PAGE, and gels were imaged for eGFP. Band intensities were analyzed and percent 
dimerization values were determined as described in section 5.5.5. Figure 5.3 presents 
averaged dimerization data for multiple trials. There is clear dose-dependent dimerization 
in response to E2, however we do not yet consider these data to be quantitative.  
We wanted to analyze the effects of other drugs on dimerization of ERα. Broadly 
speaking, antiestrogens tend to fall into two classes of compounds: selective estrogen 
receptor modulators (SERMs), which can behave as agonists or antagonists under different 
sets of conditions, and selective estrogen receptor degraders (SERDs), which cause 
conformational changes in ERα that lead to its degradation via the ubiquitin proteasome 
system.5,12,13 The active metabolite of TMX, 4-OHT, acts as a SERM; thus we chose to 
assay for dimerization in response to 4-OHT. We additionally chose to assay for 
dimerization in response to the marketed drug fulvestrant (ICI 182,780) as a prototypical 
SERD.  
 
Figure 5.2. Dimerization interface in the LBD of ERα. H516 is shown as blue 
spheres/sticks, and E2 is shown as red spheres. PDB ID 1A52 
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The results from photolysis of cells expressing ERα H516N3Phe that were treated 
with 4-OHT are shown in Figure 5.4. Note the appearance of two bands of comparable 
molecular weight in the region of the dimer. We believe the lower molecular-weight band 
is due to crosslinking of full-length ERα to truncated monomer, given the similar difference 
in mass observed for the non-crosslinked full-length ERα versus truncated protein. This 
second band was observed in all gels. For our determinations of percent dimerization, we 
only analyzed the higher-mass band. As with E2, we observed dose-dependent 
dimerization in response to 4-OHT. However, it appears that the greatest [4-OHT] we 
tested did not induce a maximal percent dimerization, as the fit does not level off. Future 
experiments will be needed to construct a full dose-response curve for dimerization 
induced by 4-OHT. The results from photolysis of cells expressing ERα H516N3Phe that 
were treated with fulvestrant are shown in Figure 5.5. Fulvestrant likewise caused dose-
dependent dimerization, although there was substantial scatter at higher concentrations of 
fulvestrant.  
 
Figure 5.3. Dimerization of eGFP-ERα in response to E2, as measured using our 
photocrosslinking assay. 
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At this point, we do not consider a quantitative comparison of the data to be 
appropriate; the assay needs to be optimized and data need to be replicated and should be 
considered preliminary. In all cases, we do observe some amount of baseline dimerization 
of ERα as well that cannot be ascribed to the action of the drugs. This will have to be 
reconciled in future experiments. Also, in the above-described experiments we use an 
eGFP-tagged ERα construct, which to some extent defeats the purpose of our minimally-
perturbing method of photocrosslinking. Future studies could use immunoblotting of 
untagged ERα with anti-ERα antibodies to circumvent this issue, but for now we wanted 
to test the method in the simplest way possible.  
 
Figure 5.4. Dimerization of eGFP-ERα in response to 4-OHT, as measured using 
our photocrosslinking assay. “F.L.” = Full-length 
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We further note that dimerization in response to 4-OHT and fulvestrant has been 
previously observed using other methodologies.19,20 What the above-described research 
represents, however, is an alternative approach for studying ERα function that offers great 
chemical precision. It is well-appreciated that the function of ERα is a complex problem; 
there have even been conflicting results regarding ERα dimerization in response to 
fulvestrant that have been reported in the literature – in some systems it blocks dimerization 
while in others it promotes dimerization.19,20,23,24 Considering the minimal amount of 
manipulation that needs to be introduced to study ERα dimerization using our approach, 
we hope that future research using this strategy may provide more clarity into the 
dimerization of ERα in response to different stimuli.  
 
Figure 5.5. Dimerization of eGFP-ERα in response to fulvestrant, as measured 
using our photocrosslinking assay. “F.L.” = Full-length; “ICI” = ICI 182,1780 
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5.3.2 Probing for cofactor interactions with the ERα NTD using photocrosslinking 
 Interactions between ERα and coregulatory proteins are key determinants of 
receptor function.6,25 Hundreds of proteins have been identified that interact with ERα, 
many of which affect transcriptional activity of the receptor.6,26 Recall from section 1.2 
that ERα contains two transcriptional “activation functions,” AF-1 in the NTD and AF-2 
in the LBD. AF-2 is chiefly responsible for the increase in transcriptional activity of ERα 
in response to activating estrogens, however AF-1 often contributes more to transcriptional 
activity than AF-2.27 Moreover, there is growing evidence that AF-1 is the predominant 
contributor to differential actions of ERα (and other steroid hormone receptors) in different 
tissues.27–29 
The ERα LBD is able to fold independently of the rest of the protein and is 
amenable to crystallization; thus interactions between this region of ERα and coregulatory 
proteins are relatively well-characterized.27,30–32 Information regarding interactions 
between coregulatory proteins and the ERα NTD, however, is sparser.27 The ERα NTD is 
largely intrinsically disordered and as such has never been crystallized with or without 
coregulatory proteins. This very intrinsic disorder, however, is likely an important aspect 
of regulation of AF-1: intrinsically disordered regions are known to promote highly 
specific yet low-affinity binding interactions via induced fit, which is ideal for transient 
regulation of signaling via transcription factors like ERα.9,11,27,33–35  
Photocrosslinking using site-specific incorporation of NCAAs is especially well-
suited for studying weak interactions such as those that would exist between coregulatory 
proteins and the ERα NTD.36 Methods like co-immunoprecipitation that rely on 
noncovalent interactions between proteins would likely miss the weak interactions between 
121 
 
proteins and the intrinsically disordered NTD. Bifunctional chemical crosslinkers could be 
used to form a covalent complex, however these rely on the presence of reactive groups 
and surface-accessibility of the protein-protein interface of interest and are not site-
specific.21,37 Feeding cells photoactivatable NCAAs that can be incorporated using 
endogenous translational machinery offers yet another alternative, but also lacks precise 
site-specificity, which could complicate analysis.38 We therefore set out to apply site-
specific incorporation of the NCAA N3Phe in the ERα NTD in order to probe for 
interactions with coregulatory proteins.  
Our approach is depicted in Figure 5.6. We aimed to first incorporate N3Phe site-
specifically using the synthetase method (section 1.3) into all of the positions in the ERα 
AF-1 that exist as aromatic amino acids in the wild-type receptor. All-told, we identified 
16 sites for modification: Y52, Y54, Y60, F62, Y73, Y80, F89, F97, H112, F120, H124, 
Y130, Y131, Y139, F149, and Y150. These residues were chosen based on previous work 
 
Figure 5.6. Envisioned strategy for using photocrosslinking to study interactions 
between coregulatory proteins (CoReg) and the ERα NTD. N3Phe is depicted as a 
yellow star. 
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identifying residues 50 to 150 of the NTD as containing the ERα AF-1.39 The ultimate goal 
was to then irradiate these receptors, analyze initially for hits by SDS-PAGE and 
immunoblotting, and identify the crosslinked species by mass spectrometry. This would 
require purification of the crosslinked complexes, so we used a C-terminally His6-tagged 
ERα. This way, with the affinity tag on the C-terminus, only full-length products would 
contain the His6 tag for visualization and purification. 
 The results from our scan of aromatic residues in AF-1 of ERα are shown in Figure 
5.7. N3Phe was incorporated into ERα-His6 in HEK293T cells at the indicated positions, 
cells were irradiated with UV light for each experimental condition alongside a negative 
control dish that was not irradiated, and cells were lysed, subjected to SDS-PAGE, and 
immunoblotted as described in section 5.5.4. 
Looking just at the results from the negative control (-h) lysates, many bands are 
typically present; this is something that we have observed previously with wild-type ERα-
His6. We presume these heavier bands are ubiquitinated ERα; their presence is fairly 
consistent across experiments and we also observe lower molecular weight bands that may 
be proteolysis products. Thus the important thing to look for is not merely the presence of 
bands other than the ERα monomer band, but bands that appear only upon UV irradiation. 
Comparing -h lysates to +h lysates, we believe that we have identified several 
sites in the ERα NTD that have been crosslinked to some other species. In the absence of 
further verification of these hits, we hesitate to make any absolute claims, but it appears 
that there was an appreciable amount of crosslinking at least for F149N3Phe and 
Y150N3Phe, and perhaps weaker crosslinking of Y60N3Phe, F62N3Phe, F89N3Phe, 
F120N3Phe, and Y139N3Phe. We believe in these cases that we have observed crosslinking 
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due to two key observations: 1) the appearance of new bands in the +h lysates compared 
to the -h lysates, indicating the formation of some new species that is recognized by an 
anti-His6 antibody only if the samples are irradiated with UV light, and 2) the site-
 
Figure 5.7. Western blots using photocrosslinking of N3Phe to probe for interactions 
between coregulatory proteins and the AF-1 of the ERα NTD. Results continue on the 
next page… 
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specificity of the appearance of these new bands, given that some sites did not yield 
apparent crosslinking, which would imply that the appearance of the purportedly 
crosslinked species is not a mere fluke of the system. Unfortunately, in the experiments 
involving Y54, F97, and H124, lysates from the unirradiated dishes in these experiments 
 
Figure 5.7. …continued from previous page. 
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did not have good expression of ERα, so we do not have a negative control for these, but 
it does appear that ERα H124N3Phe was successfully crosslinked in the +h experiment.  
 The end goal of the above-described work is to use the photocrosslinking strategy 
to identify new coregulatory partners of the ERα AF-1 and/or quantify changes in the 
interactome of AF-1 in response to different stimuli. Either of these goals would benefit 
from the ability to purify the crosslinked complexes and analyze them by mass 
spectrometry. Initial efforts in our lab to purify crosslinked ERα complexes via FPLC using 
a Ni-NTA column have not been successful, likely owing to the abundance of other nickel-
binding species natively expressed in HEK293T cells. Future efforts to purify crosslinked 
ERα complexes may involve a forward/reverse immobilized metal affinity 
chromatography (IMAC) strategy, in which nickel-binding species are first purified by 
affinity chromatography with a Ni-NTA column, the His6 tag is removed from the ERα 
complex with a protease, and IMAC is again performed but the flowthrough is collected 
instead of the species that bind the column.40 We have introduced a cut site for TEV 
protease into our ERα-His6 plasmid (see section 5.5.1) just upstream of the C-terminal His6 
tag in order to pursue this forward/reverse IMAC strategy. 
5.4 Conclusions & Future Directions 
 The work described herein has sought to use site-specific incorporation of the 
photocrosslinking NCAA, N3Phe, to gain insights into ERα function. We have built upon 
previous work in our lab to demonstrate dimerization of eGFP-ERα in response to the 
clinically-relevant drugs 4-OHT and fulvestrant using a novel strategy that may find future 
applications as a minimally-perturbing means of probing receptor dimerization of ERα and 
other receptors. We have also demonstrated the potential utility of site-specific 
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incorporation of N3Phe for studying interactions with the intrinsically disordered NTD of 
ERα.  
 There are many potential future directions for this research. The work on ERα 
dimerization could be expanded upon to create a more robust system for studying 
dimerization of ERα and other receptors in vivo in response to different stimuli. Contingent 
upon successful purification of crosslinked ERα complexes and identification of binding 
partners by mass spectrometry, the approach we’ve used herein could be used to study how 
regulatory proteins interact with the ERα NTD and similar disordered regions of other 
proteins. Variables within the system, of which there are many that influence ERα function, 
could then be changed systematically to ultimately gain a better understanding of the roles 
coregulatory proteins play in modulating the response of ERα (and other steroid hormone 
receptors).  
5.5 Experimental Procedures 
5.5.1 Molecular biology 
 The gene ESR1 for human ERα was in the pcDNA3.1(+) expression vector with a 
C-terminal His6 tag. The N-terminal eGFP ERα fusion protein was also in the 
pcDNA3.1(+) vector, with a 15-residue linker, SGRSRAASNSAVDGT, between the C-
terminus of eGFP and the N-terminus of ERα. Mutations were introduced using a 
QuikChange mutagenesis kit (Stratagene). Introduction of a TEV protease restriction site 
immediately N-terminal to the His6 tag of the ERα-His6 construct was accomplished using 
an established two-stage PCR protocol with the QuikChange kit.41  
 A PU6 plasmid encoding the tRNA/synthetase pair for N3Phe was a kind gift from 
the lab of Professor Michelle Krogsgaard (New York University).22  
127 
 
5.5.2 Mammalian cell culture and protein expression 
 HEK293T cells (ATCC) were aliquoted from a low passage number monolayer 
culture, stored in large liquid nitrogen dewar, and thawed and recovered for use as per 
standard procedure.42 Cells were grown in DMEM/F12 (Gibco) supplemented with 10% 
heat-inactivated FBS (Gibco) and 100 U/mL penicillin and 100µg/mL streptomycin at 
37ºC under 5% CO2 and passaged every 2-4 days once they reached 80-90% confluence. 
All routine manipulations of HEK293T cells were performed in a class II biosafety cabinet.  
 For expressing proteins of interest, cells were subcultured in 35-mm petri dishes 
from a parent monolayer culture and incubated until 50-75% confluent prior to transfection. 
Transfection was carried out using the Xfect reagent (Clontech) by premixing plasmid 
DNA and Xfect buffer before adding Xfect polymer (0.3µL polymer / 1µg DNA). For 
expression of wild-type ERα, 5µg of plasmid DNA was transfected. For nonsense 
suppression experiments, 5-7.5µg of ERα plasmid DNA was transfected alongside 2.5µg 
of the PU6 plasmid encoding the tRNA/synthetase pair for N3Phe.  
Following preparation of the appropriately-diluted transfection mixture, the cell 
culture medium for each dish was replaced with 900µL of fresh medium and 100µL of 
transfection mixture was added. Transfections were incubated at 37ºC under 5% CO2 for 
3-4h, at which point the medium was discarded and replaced with 3mL of fresh medium 
containing 0.5mM N3Phe in the case of nonsense suppression experiments.  
Cells were grown for ~24h to allow for expression of protein before addition of 
drugs of interest. ß-estradiol (E2; Sigma-Aldrich), (Z)-4-hydroxytamoxifen (4-OHT; 
Sigma-Aldrich), and ICI 182,780 (Sigma-Aldrich) were prepared as stock solutions in 
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DMSO and stored at -20ºC. Drugs were added in 30µL DMSO to dishes containing 3mL 
of medium and incubated 16-24h prior to irradiation for photocrosslinking and/or lysis.  
5.5.3 Photocrosslinking 
 Following ~48h total incubation time post-transfection, photocrosslinking was 
performed on cells expressing ERα incorporating N3Phe. 0-60min prior to irradiation, cell 
culture medium was discarded and replaced with 1mL of fresh medium not containing 
N3Phe or drug. Dishes were then irradiated from below at a distance of 1-2cm with a 
1150mW 365nm LED (Thorlabs) for 20min. Cells were immediately lysed and put on ice 
following photocrosslinking. Photocrosslinking was carried out separately for each cell 
culture dish / condition.  
5.5.4 Lysis, SDS-PAGE, and immunoblotting 
 Following protein expression and, in most experiments, photocrosslinking, cells 
were lysed in 200-500µL of lysis buffer and immediately put on ice prior to storage at -
80ºC. For most experiments, cells were lysed in 1% SDS in PBS with protease inhibitors, 
followed by a 10s sonication with an immersion sonicator.  
 For separation by SDS-PAGE, 12µL of lysate were mixed with 3µL of a 5X stock 
solution containing 5% SDS, 25% glycerol, 250mM Tris, and 0.5mg/mL bromophenol 
blue, and loaded into precast Biorad Mini-Protean TGX 15-well gels with an AnykD 
gradient. 1µL of Precision Plus Protein Dual Color Standard (Bio-Rad) was used for 
molecular weight calibrations. Gels were run at 150V for 45-60min prior to imaging and/or 
transfer for immunoblotting.  
 For immunoblotting, LF-PVDF membranes (Bio-Rad) were soaked for 10min in 
neat methanol immediately prior to transfer at 4ºC in Towbin’s Buffer (prepared in-house) 
129 
 
at 30mV for 30min, followed by 100V for 90min. The membranes were then incubated at 
4ºC in 5% milk in TPBS (PBS containing 0.1% Tween-20) for ~1h, and subsequently 
incubated at 4ºC with 1µg/mL of mouse anti-His6 primary antibody (AD1.1.10; Novus 
Biologicals) in 5% milk TPBS for ~24h. Blots were then washed four times for five minutes 
per wash with TPBS, prior to incubation for ~2h with AzureSpectra 700 goat anti-mouse 
secondary antibody (Azure Biosystems) in 5% milk TPBS. Blots were finally washed three 
times at five minutes per wash followed by once at 30min with TPBS prior to imaging.  
5.5.5 Imaging & data analysis 
 For imaging of eGFP ERα, we used a Typhoon FLA 9000 with a 473nm laser 
excitation and a LPB (510LP) detection filter. Imaging of immunoblots was performed on 
a LI-COR Odyssey with a 685nm laser excitation and 700nm detection. Adjustment to 
brightness/contrast and quantification of band intensities were performed in ImageJ. Peak 
intensities were determined by integrating the area under the curve using the “wand” tool 
for a representative 10-pixel-wide slice including the peak maximum, and percent 
dimerization values were calculated from these values. Assignment of dimer bands was 
made by comparing to the Precision Plus Protein Dual Color Standard (Bio-Rad) molecular 
weight ladder, and by visual comparison with previously-observed results (DOI 
10.7907/Z9G44N8W). Plots were generated in Prism 7 and fits were made via the in-suite 
four parameter variable slope nonlinear regression. 
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